[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 106
1. Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, Miyatake T, Fujita M, Lee CM, Morimoto K, Fujimoto M, Kimura T, Naka T: Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer; 2009 Nov 15;125(10):2316-22
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
  • Clear cell carcinoma (CCC) of the ovary is known to be highly resistant to platinum-based chemotherapy.
  • Anx A4 levels were elevated in CCC cells compared with non-CCC cells as determined by real-time RT-PCR and Western blot analysis.
  • Immunohistochemical analysis of Anx A4 was performed in 126 epithelial ovarian cancer tissue samples and demonstrated significantly elevated levels of Anx A4 protein levels in ovarian CCC tumors compared with ovarian serous and endometrioid tumors (p < 0.01).
  • Intracellular platinum levels were significantly lower in Anx A4-transfected cells compared with control cells after carboplatin treatment (p = 0.0020) and after an additional 360 min of carboplatin-free incubation (p = 0.0004), as measured by atomic absorption spectrophotometry.
  • These results demonstrate that Anx A4 confers chemoresistance in ovarian cancer cells in part by enhancing drug efflux.
  • Thus, Anx A4 may represent a novel therapeutic target of chemoresistance in patients with ovarian CCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Annexin A4 / metabolism. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunoenzyme Techniques. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19598262.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A4; 0 / Antineoplastic Agents; 0 / RNA, Messenger; BG3F62OND5 / Carboplatin
  •  go-up   go-down


2. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res; 2009 Sep 1;15(17):5404-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
  • PURPOSE: Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer.
  • This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype.
  • EXPERIMENTAL DESIGN: Using tissue microarrays of 98 primary ovarian cancers (52 clear cell carcinomas and 46 serous adenocarcinomas), the expression of phospho-mTOR was assessed by immunohistochemistry.
  • Then, the growth-inhibitory effect of mTOR inhibition by RAD001 (everolimus) was examined using two pairs of cisplatin-sensitive parental (RMG1 and KOC7C) and cisplatin-resistant human clear cell carcinoma cell lines (RMG1-CR and KOC7C-CR) both in vitro and in vivo.
  • Treatment with RAD001 markedly inhibited the growth of both RMG1 and KOC7C cells both in vitro and in vivo.
  • CONCLUSION: mTOR is frequently activated in clear cell carcinoma and can be a promising therapeutic target in the management of clear cell carcinoma.
  • Moreover, mTOR inhibition by RAD001 may be efficacious as a second-line treatment of recurrent disease in patients previously treated with cisplatin.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):336-44 [18639330.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5853-7 [15208673.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):643-9 [15350353.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):414-8 [3539322.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5315-22 [9478990.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7418-26 [15534119.001]
  • [Cites] Cell. 2005 Mar 25;120(6):747-59 [15797377.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1533-40 [16227402.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6 [16445610.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):71-5 [16290000.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1761-9 [16396982.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):292-9 [16443261.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):285-91 [16516283.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):138-43 [16847906.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1545-51 [16884363.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5988-94 [11085518.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2448-54 [12114452.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33490-500 [12087097.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1491-501 [12820963.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):123-9 [14529671.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):252-61 [14729632.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1013-23 [14871980.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23477-85 [15026414.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1932-40 [17001314.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):404-8 [17292461.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4261-70 [17634556.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Autophagy. 2008 May;4(4):467-75 [18259115.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • (PMID = 19690197.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA06927; United States / NCI NIH HHS / CA / CA083638-10; United States / NCI NIH HHS / CA / CA077429-02; United States / NCI NIH HHS / CA / P30 CA006927-45; United States / NCI NIH HHS / CA / CA83638; United States / NCI NIH HHS / CA / R01 CA077429; United States / NCI NIH HHS / CA / P50 CA083638-10; United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / R01 CA077429-02; United States / NCI NIH HHS / CA / CA77429; United States / NCI NIH HHS / CA / P30 CA006927
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; Q20Q21Q62J / Cisplatin; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS125079; NLM/ PMC2743856
  •  go-up   go-down


3. Coleman RL: Emerging role of topotecan in front-line treatment of carcinoma of the ovary. Oncologist; 2002;7 Suppl 5:46-55
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging role of topotecan in front-line treatment of carcinoma of the ovary.
  • The conventional front-line chemotherapy strategy for advanced epithelial ovarian carcinoma has become adjuvant administration of platinum (carboplatin and cisplatin), either alone or, most often, in combination with a taxane.
  • One agent, topotecan, has antitumor activity comparable with paclitaxel in patients with recurrent ovarian cancer and is an established treatment in second-line or salvage settings.
  • These properties, coupled with the in vitro synergy observed in tumor models among topotecan, paclitaxel, and platinum, have provided the rationale for investigators to examine topotecan in front-line ovarian cancer therapy.
  • A number of strategies for incorporating topotecan into front-line therapy are under active investigation, including the replacement of paclitaxel with topotecan, a triplet regimen with cisplatin or carboplatin and paclitaxel, a consolidation regimen consisting of several courses of a platinum agent and paclitaxel followed by several courses of topotecan, and a sequential doublet regimen in which patients receive platinum in every course as part of a doublet with alternating or sequential topotecan and paclitaxel.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Enzyme Inhibitors / administration & dosage. Ovarian Neoplasms / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance, Neoplasm. Drug Therapy, Combination. Female. Humans. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12324633.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 7M7YKX2N15 / Topotecan
  • [Number-of-references] 38
  •  go-up   go-down


Advertisement
4. Wynn D, Everett GD, Boothby RA: Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status. Gynecol Oncol; 2004 Dec;95(3):716-8
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status.
  • BACKGROUND: Small cell carcinoma of the ovary is a rare, highly malignant tumor that often exhibits a paraneoplastic hypercalcemia.
  • Further investigation revealed a left ovarian mass and a small cell carcinoma of the ovary, hypercalcemic type was found.
  • Hysterectomy with bilateral salpingo-oophorectomy was performed, and the patient underwent chemotherapy with carboplatin and paclitaxel.
  • Hypercalcemia resolved after tumor resection.
  • Small cell carcinoma of the ovary should be considered under these circumstances.
  • [MeSH-major] Carcinoma, Small Cell / complications. Hypercalcemia / complications. Ovarian Neoplasms / complications. Ovarian Neoplasms / pathology. Pancreatitis / etiology

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581988.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Hafezi-Bakhtiari S, Morava-Protzner I, Burnell MJ, Reardon E, Colgan TJ: Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment. J Obstet Gynaecol Can; 2010 Jul;32(7):698-702
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment.
  • BACKGROUND: Choriocarcinoma within an ovarian carcinoma is exceptionally rare.
  • Nevertheless, recognition of this mixed tumour is important for administration of appropriate chemotherapy.
  • On pathologic examination the mass showed a choriocarcinoma in association with a serous carcinoma.
  • This pathologic diagnosis led to a specific chemotherapy regimen with cisplatin, etoposide, and bleomycin, suitable for both types of malignancy.
  • CONCLUSION: Both gynaecologists and pathologists should be aware that the histopathologic classification of ovarian epithelial carcinoma and its variants, such as this one, may have an increasing role in the management of this disease.

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20707961.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


6. Saitoh-Sekiguchi M, Nakahara K, Kojimahara T, Ohta T, Kawagoe J, Ohnuki T, Hayasaka T, Motoyama T, Kurachi H: Complete remission of ovarian small cell carcinoma treated with irinotecan and cisplatin: a case report. Anticancer Res; 2007 Jul-Aug;27(4C):2685-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of ovarian small cell carcinoma treated with irinotecan and cisplatin: a case report.
  • BACKGROUND: Small cell carcinoma of the ovary is a rare type of ovarian carcinoma with a very poor prognosis.
  • CASE REPORT: We report here a case of a 55-year-old woman with small cell carcinoma of the left ovary.
  • The patient underwent cytoreductive surgery with residual tumors of 6 cm at the cul-de-sac and was found to have stage IIIc disease.
  • After six courses of irinotecan (CPT-11) and cisplatin (CDDP) combination therapy, secondary cytoreductive surgery was performed.
  • After an additional three courses of chemotherapy, the patient is still alive and well without evidence of disease.
  • CONCLUSION: CPT-11 and CDDP combination chemotherapy may be effective and safe for patients with small cell carcinoma of the ovary.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695433.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Kesterson JP, Mhawech-Fauceglia P, Lele S: The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol; 2008 Dec;111(3):527-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.
  • BACKGROUND: The potential role of bevacizumab in the treatment of ovarian granulosa-cell tumors has not been evaluated.
  • CASE: An 82 year old woman with refractory ovarian granulosa-cell carcinoma was treated with bevacizumab with symptomatic relief of ascites.
  • CONCLUSION: Bevacizumab may have a role in the management of malignant ascites in the patient with refractory granulosa-cell carcinoma of the ovary which should be confirmed in a larger series of well selected patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulosa Cell Tumor / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Ascites / drug therapy. Bevacizumab. Female. Humans. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5165-71 [18024863.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):72-8 [18394773.001]
  • [Cites] Gynecol Oncol. 2006 Sep;102(3):425-8 [16797681.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):131-3 [16846774.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):140-4 [16790264.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):134-9 [16527339.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Jan;53(1):68-74 [14569416.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5180-6 [18024865.001]
  • (PMID = 18710781.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA108456
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Parasassi T, Brunelli R, Bracci-Laudiero L, Greco G, Gustafsson AC, Krasnowska EK, Lundeberg J, Lundeberg T, Pittaluga E, Romano MC, Serafino A: Differentiation of normal and cancer cells induced by sulfhydryl reduction: biochemical and molecular mechanisms. Cell Death Differ; 2005 Oct;12(10):1285-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In human normal primary keratinocytes and in colon and ovary carcinoma cells we obtained evidences for: (i) a dose-dependent inhibition of proliferation without toxicity or apoptosis;.
  • In conclusion, a thiol reduction devoid of toxicity as that operated by NAC apparently leads to terminal differentiation of normal and cancer cells through a pleiade of converging mechanisms, many of which are targets of the recently developed differentiation therapy.
  • [MeSH-minor] Acetylcysteine / pharmacology. Cadherins / metabolism. Cell Adhesion / drug effects. Cell Adhesion / physiology. Cell Adhesion Molecules / metabolism. Cell Line, Tumor. Cytoskeletal Proteins / metabolism. Female. Humans. Keratinocytes / cytology. Keratinocytes / drug effects. Keratinocytes / metabolism. Phosphotransferases / antagonists & inhibitors. Phosphotransferases / metabolism. Protein-Tyrosine Kinases. Proto-Oncogene Proteins / antagonists & inhibitors. Proto-Oncogene Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Thymidine / metabolism. Trans-Activators. beta Catenin. src-Family Kinases

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920536.001).
  • [ISSN] 1350-9047
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Cytoskeletal Proteins; 0 / Proto-Oncogene Proteins; 0 / Sulfhydryl Compounds; 0 / Trans-Activators; 0 / beta Catenin; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / CSK tyrosine-protein kinase; EC 2.7.10.2 / src-Family Kinases; VC2W18DGKR / Thymidine; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


9. Fujiwara K, Suzuki S, Ishikawa H, Oda T, Aotani E, Kohno I: Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int J Gynecol Cancer; 2005 May-Jun;15(3):426-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube.
  • The objective of this study was to provide preliminary toxicity data of multiple-cycle combination chemotherapy with intraperitoneal (IP) carboplatin and intravenous (IV) paclitaxel for further clinical trials.
  • The toxicity data of 42 patients with mullerian carcinoma who underwent IP carboplatin therapy in combination with IV paclitaxel were retrospectively analyzed.
  • Chemotherapy was repeated through the Bard IP port placed at initial surgery using IV paclitaxel at 175 mg/m2 followed by IP carboplatin.
  • The median number of cycles for IP chemotherapy was 6 (range: 3-12).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Female. Humans. Infusions, Intravenous. Infusions, Parenteral. Middle Aged. Paclitaxel / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882165.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J, Tode T, Nagata I: Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep; 2000 Mar-Apr;7(2):327-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.
  • Although clear cell carcinoma of the ovary is considered to be a tumor with poor prognosis, the clinical characteristics has not been defined.
  • The aim of this study was to evaluate the response of clear cell carcinoma of the ovary to first and second-line chemotherapy and explore effective chemotherapy.
  • Fifty-three patients with clear cell carcinoma of the ovary were enrolled between 1988 and 1997 at our department.
  • Since taxol was not available in Japan at that time, cisplatin-based combination chemotherapy has been exclusively used as a standard first-line chemotherapy.
  • Retrospective analyses of clinical characteristics and the response to first or second-line chemotherapy were performed.
  • Out of 25 patients with III or IV stage disease 20% (5/25) had negative residual tumor, 36% (9/25) had <2 cm residual tumor, and 44% (11/25) had >/=2 cm residual tumor.
  • All patients received postoperative platinum-based chemotherapy.
  • Of 23 patients with measurable residual tumor 8.7% (2/23) completely and 13% (3/23) partially responded to first-line chemotherapy consisting of cisplatin, adriamycin and cyclophosphamide (CAP) or cisplatin and cyclophosphamide (CP) by CT scan or second look laparotomy.
  • Although overall response rate of ovarian clear cell carcinoma to first-line chemotherapy by CAP or CP was about 22%, EP or EJ consisting of etoposide and cisplatin or carboplatin used as a second-line chemotherapy showed 29% response rate, while CPT-P consisting of CPT-11 and cisplatin showed 40% response rate.
  • Although patients with advanced ovarian clear cell carcinoma seemed to have better response to CPT-P than conventional platinum-based chemotherapy, further studies are required with larger number of patients to draw firm conclusions.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10671681.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 49DFR088MY / Platinum; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Crawford SM, Peace J: Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol; 2005 Jan;16(1):47-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
  • The tumour marker CA125 is an important indicator of the clinical progress of women with carcinoma of the ovary.
  • We have investigated the interval from the nadir CA125 value to progression defined by rising CA125 (time to biochemical progression, TBP), and overall survival of patients treated with chemotherapy for this disease in relation to the nadir CA125 value in patients in whom this was <30 U/ml following chemotherapy.
  • This prognostic indicator will be useful in studying the management of patients following response to first-line chemotherapy.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2005 Jun;2(6):288-9 [16264982.001]
  • (PMID = 15598937.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


12. Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, Yu MH, Mao TL, Wang TY, Hsieh CY: Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol; 2004 Jul;94(1):197-203
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
  • OBJECTIVE: The aim was to compare survival in pure and mixed-type advanced clear cell ovarian carcinoma and to determine the benefits among patients with pure advanced clear cell ovarian carcinoma treated in paclitaxel-platinum-based chemotherapy in comparison with those treated in conventional platinum-based chemotherapy after primary surgery.
  • METHODS: Between 1994 and 2001, 31 women with stage III and IV pure clear cell ovarian carcinoma and nine patients with stage III and IV mixed-type clear cell carcinoma were identified from the tumor registry of six institutions.
  • All patients underwent cytoreductive surgery followed by conventional platinum-based chemotherapy or paclitaxel and platinum-based chemotherapy.
  • RESULTS: The median survival of women with pure clear cell carcinoma was 11 months, compared to 48+ months for those with mixed-type clear cell carcinoma (P = 0.003).
  • Overall, for women with pure clear cell carcinoma, 35% had clinically complete responses to chemotherapy.
  • For women with pure clear cell carcinoma treated with paclitaxel-platinum-based chemotherapy, the median survival was significantly longer than for those treated with conventional platinum-based chemotherapy (16.26 vs. 10.75 months, P = 0.045; with optimal cytoreduction, 40.95 vs. 9.02 months, P = 0.028).
  • Univariate analysis showed paclitaxel-platinum-based treatment was the only favorable prognostic factor for women with advanced pure clear cell ovarian carcinoma (P = 0.05).
  • CONCLUSIONS: Patients with advanced pure clear cell ovarian carcinoma have poorer prognoses than those with the mixed type.
  • Paclitaxel-platinum-based chemotherapy improved survival among our patients with advanced pure clear cell carcinoma, especially for those with optimal cytoreduction.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15262142.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Bryant CS, Shah JP, Triest JA, Schimp VL, Morris RT: Bladder erosion by an intraperitoneal chemotherapy catheter resulting in catheter protrusion through the external urethral meatus. Gynecol Oncol; 2008 Dec;111(3):552-4
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder erosion by an intraperitoneal chemotherapy catheter resulting in catheter protrusion through the external urethral meatus.
  • BACKGROUND: Chemotherapy remains an essential part of the treatment of advanced ovarian cancer.
  • Intraperitoneal (IP) administration has been demonstrated to provide a survival advantage over intravenous chemotherapy in three phase 3 studies.
  • However, IP catheter complications have been a significant factor in aborting IP therapy.
  • CASE: A 42-year-old woman receiving IP chemotherapy for carcinoma of the ovary presented with complaints of incontinence.
  • IP chemotherapy was resumed 16 days postoperatively without incident.
  • Increased usage of IP chemotherapy may offer new challenges in the diagnosis and management of catheter-related complications.
  • [MeSH-minor] Adult. Female. Humans. Infusions, Parenteral. Ovarian Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289650.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF: Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. Gynecol Oncol; 2002 Jun;85(3):459-63
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary.
  • OBJECTIVE: Malignant mixed müllerian tumor (MMMT) of the ovary is a rare tumor with a dismal prognosis.
  • The most effective therapy is unknown.
  • The current study was undertaken to characterize a group of patients treated as if they had aggressive epithelial ovarian tumors, with cytoreductive surgery and combination paclitaxel/platinum chemotherapy.
  • METHODS: Retrospective analysis of data obtained from tumor registry and hospital records of cases of malignant mixed müllerian tumor between January 1, 1992 and January 1, 2000 treated at the Massachusetts General Hospital, Brigham and Women's Hospital, and University of Vermont was performed.
  • Only patients treated with combination paclitaxel and platinum therapy were included in the analysis.
  • Data were collected regarding cytoreduction, response to chemotherapy, disease-free interval, and survival.
  • Twenty-eight patients with a clearly ovarian primary had received treatment with combination paclitaxel and platinum.
  • Paclitaxel and carboplatin was given as second-line therapy in 2 patients who had chemoresponsive but incurable disease; the remaining patients were treated with paclitaxel and platinum therapy as first-line therapy.
  • Treatment was generally well tolerated.
  • Sixteen patients of 26 treated with paclitaxel and platinum as first-line therapy achieved a complete clinical response (55%) and 6 patients achieved partial response for a total response rate of 72%.
  • Optimal cytoreduction was associated with increased time to recurrence (P = 0.001) but not with survival.
  • CONCLUSION: Although treatment fails many patients, a minority of patients with MMMT in this highly selected population do unexpectedly well.
  • An aggressive approach with surgery and combination paclitaxel-platinum chemotherapy appears to offer very effective therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12051874.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Rosa DD, Awada A, Mano MS, Selleslags J, Lebrun F, Gil T, Piccart MJ, D'Hondt V: Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Arch Gynecol Obstet; 2008 Nov;278(5):457-62
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
  • METHODS: Patients with recurrent, resistant or refractory pretreated ovarian carcinoma were eligible for oxaliplatin (85 mg/m(2)) and leucovorin (200 mg/m(2)), both given as a 2-h infusion on day 1, followed by a 48-h infusion of 5FU 2,600 mg/m(2) every 2 weeks.
  • Median number of previous chemotherapy regimens: 5 (3-10) and previous platinum-based regimens: 2 (1-3).
  • Median chemotherapy-free interval (interval since the completion of the last-line chemotherapy before the administration of the Folfox regimen): 9.5 weeks (1-39).
  • There were no grade 4 adverse events or deaths due to the treatment.
  • These results support further assessment of Folfox as salvage treatment for patients with carcinoma of the ovary or fallopian tube.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma / drug therapy. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cohort Studies. Disease-Free Survival. Female. Fluorouracil / adverse effects. Humans. Leucovorin / adverse effects. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273626.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


16. Pusiol T, Zorzi MG, Morichetti D, Piscioli I, Scialpi M: Peritoneal Malignant Psammomatous Mesothelioma. World J Oncol; 2010 Aug;1(4):179-181

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal Malignant Psammomatous Mesothelioma.
  • Psammoma bodies (PBs) are observed most commonly in papillary thyroid carcinoma, meningioma, and papillary serous cystadenocarcinoma of the ovary.
  • We report one case of peritoneal malignant mesothelioma (PMM) with massive deposition of PBs.
  • Contrast enhanced computed tomography showed fluid diffuse in peritoneal recesses, thick septa with micronodules in the greater omentum and adjacent enhancement of the thickened peritoneum.
  • The peritoneal biopsy revealed a superficial papillary growth of malignant epithelial-like cells with diffuse involvement of submesothelial tissues.
  • The patient was treated with chemotherapy (gemcitabine, vinorelbine, cisplatin).
  • PBs may represent an active biologic process ultimately leading to degeneration/death of tumor cells and retardation of growth of the neoplasm.
  • It may also serve as a barrier against the spread of tumor.
  • Psammomatous malignant mesothelioma may simulate serous psammocarcinoma of the peritoneum.
  • The behavior of serous psammocarcinoma is more closely similar to borderline serous tumor than to serous carcinoma.
  • Further studies are necessary to establish if massive deposition of PBs may define a new variant of psammomatous malignant mesothelioma with a favorable impact to the prognosis of usual psammomatous malignant mesothelioma, as well as in serous psammocarcinoma of the peritoneum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):285-94 [10680897.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):816-23 [10843283.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Histopathology. 2006 Feb;48(3):223-32 [16430468.001]
  • [Cites] Arch Gynecol Obstet. 2009 Jun;279(6):931-6 [18982336.001]
  • [Cites] Acta Med Port. 2002 Sep-Oct;15(5):383-6 [12645223.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Diagn Cytopathol. 2009 Jul;37(7):534-41 [19373908.001]
  • (PMID = 29147203.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Malignant mesothelioma / Psammoma bodies / Psammomatous malignant mesothelioma
  •  go-up   go-down


17. Takami M, Kita E, Kuwana Y, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Ichikawa G, Yamamoto T: [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1243-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
  • Clear-cell carcinoma of the ovary is a highly malignant neoplasm.
  • Survival of patients in the advanced stage is poor, and the best treatment is not clear.
  • We report here a case of a 57-year-old woman who had Stage IIIb advanced clearcell carcinoma of the ovary.
  • After the operation she was placed on induction and maintenance chemotherapy with a combination of irinotecan(CPT-11)(60 mg/m2, day 1, 15)plus cisplatin(CDDP)(60 mg/m2, day 1).
  • Four years after surgery, a metastatic tumor was found in the brain.
  • Considering the poor prognosis of clear-cell carcinoma, this regimen is thought to be effective for advanced clear-cell carcinoma of the ovary.
  • It is important to check brain metastases under maintenance chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633273.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Nieves L, Currie J, Hoffman J, Sorosky JI: Ototoxicity after intraperitoneal chemotherapy: a case report. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1133-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ototoxicity after intraperitoneal chemotherapy: a case report.
  • Recently, the National Cancer Institute endorsed intraperitoneal (IP) therapy as the treatment of choice for optimally debulked epithelial ovarian cancer.
  • However, there are no drug regimens that are clearly indicated, and the exact method of administration has not been established.
  • Furthermore and most importantly, physicians are unaware of what toxicities should be expected with their use of IP therapy.
  • We report a recent unanticipated toxicity from IP cisplatin therapy and review the literature.
  • A 63-year-old female with optimally debulked stage IIIC papillary serous carcinoma of ovary was admitted on postoperative day 14 for her first cycle of IP cisplatin.
  • [MeSH-major] Cisplatin / adverse effects. Hearing Loss / chemically induced. Hearing Loss / diagnosis. Ovarian Neoplasms / drug therapy. Peritoneal Cavity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433058.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 12
  •  go-up   go-down


19. Sholler GL, Luks F, Mangray S, Meech SJ: Advanced small cell carcinoma of the ovary in a pediatric patient with long-term survival and review of the literature. J Pediatr Hematol Oncol; 2005 Mar;27(3):169-72
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced small cell carcinoma of the ovary in a pediatric patient with long-term survival and review of the literature.
  • Advanced small cell carcinoma of the ovary is very aggressive tumor with an overall poor prognosis.
  • She was treated with gross total surgical resection and multiagent chemotherapy and remains free of disease more than 2.5 years from diagnosis.
  • The treatment regimen is discussed in detail and was well tolerated, with minimal toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Child. Female. Gynecologic Surgical Procedures. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750452.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Fujiwara K, Maehata K, Kohno I, Yoden E, Imajo Y, Mikami Y: [A case of clear cell carcinoma of the ovary responding to a paclitaxel-carboplatin combination chemotherapy]. Gan To Kagaku Ryoho; 2000 Dec;27(14):2259-62
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of clear cell carcinoma of the ovary responding to a paclitaxel-carboplatin combination chemotherapy].
  • Clear cell carcinoma of the ovary is believed to be chemoresistant; therefore, choosing anticancer agents is often difficult.
  • In this report we present a case of ovarian clear cell carcinoma that showed a significant response to a combination chemotherapy with paclitaxel and carboplatin.
  • The patient is a 51-year-old Japanese female with a history of Gn-RH treatment for endometriosis that was terminated three years before the presentation of this disease.
  • The initial surgery revealed the tumor was a clear cell carcinoma of the left ovary, showing a predominantly solid growth pattern as well as papillary and tubular patterns.
  • Therefore, the tumor was considered to be grade 2.
  • Combination chemotherapy using paclitaxel at 175 mg/m2 in 3 hr intravenous infusion followed by intraperitoneal infusion of carboplatin at AUC of 7.5 as a bolus was administered.
  • We believe that the combination of paclitaxel and carboplatin is one treatment choice for clear cell carcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11142173.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Shi M, Zhang Y, Shen K, Lang J, Huang H, Wu M: [Clinical characteristics of clear cell carcinoma of the ovary]. Zhonghua Fu Chan Ke Za Zhi; 2002 Mar;37(3):161-3
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of clear cell carcinoma of the ovary].
  • OBJECTIVE: To study the clinical characteristics of clear cell carcinoma of the ovary.
  • METHODS: Forty three patients with clear cell carcinoma of the ovary and 51 patients with serous adenocarcinoma of the ovary who were admitted in Peking Union Medical College Hospital between 1984 to 2000 were analyzed retrospectively, and their chemosensitivities and the survival rates were compared.
  • RESULTS: The percentage of early stage patients in the clear cell carcinoma of the ovary and the serous adenocarcinoma of the ovary was 14.4% and 3.8% respectively, the difference was significant (P < 0.005).
  • In the late stage patients who underwent satisfactory cytoreductive surgery, the chemo-resistant rate (88.9%) in the clear cell carcinoma of the ovary was significantly higher than that (57.1%) of the serous adenocarcinoma of the ovary (P < 0.02), the 1-year survival rate (79.0%) in the clear cell carcinoma of the ovary was significantly lower than that (96.2%) of the serous adenocarcinoma of the ovary (P < 0.01).
  • In the late stage patients who underwent unsatisfactory cytoreductive surgery, the chemo-resistant rate and the survival rate had no significant difference between the clear cell carcinoma of the ovary and the serous adenocarcinoma of the ovary (P > 0.05).
  • CONCLUSIONS: There are more early stage patients with clear cell carcinoma of the ovary.
  • We should conduct auxiliary therapy and close follow up to them after surgery.
  • Clear cell carcinoma of the ovary is chemo-resistant to platinum-based chemotherapy and has poor prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Cystadenocarcinoma / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Resistance / physiology. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11953086.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Trifonov I: [Registry of patients with advanced ovary carcinoma in the province of Stara Zagora]. Akush Ginekol (Sofiia); 2007;46(7):35-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Registry of patients with advanced ovary carcinoma in the province of Stara Zagora].
  • A representative inquiry has been conducted including the most important parameters from the medical files of 61 out-patients with ovarian carcinoma in III or IV stage in the province of Stara Zagora for the period 1997, 1998 and 1999.
  • In 9.83% of the patients benign tumours were found, in 6.55% malignant as concomitant diseases.
  • In most cases the treatment is surgery in combination with chemotherapy.
  • Histological screening of ovarian tumours showed predominance of the serous carcinoma in the papilliferum--/40.98%/.
  • A combined chemotherapy. including mostly cys-platinum, is used in the treatment of patients with tumour in the ovary in the Clinic of Oncological Diseases of Stara Zagora.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333420.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


23. Seidman JD, Horkayne-Szakaly I, Cosin JA, Ryu HS, Haiba M, Boice CR, Yemelyanova AV: Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol; 2006 Nov;103(2):703-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
  • OBJECTIVE: A variety of histologic grading systems for ovarian carcinoma have been used, but there is no widely accepted system.
  • Binary grading systems are inherently superior to the more common three-grade systems because they are more reproducible and they correspond to the number of options in the binary treatment decision for which grade is considered important: the use of or withholding of chemotherapy.
  • METHODS: One hundred thirteen unselected FIGO stage III serous carcinomas of the ovary and peritoneum were tested with two grading systems: a binary system recently proposed by investigators at MD Anderson Cancer Center (MDACC) and a new binary system we formulated at the Washington Hospital Center (WHC).
  • The MDACC system separates a small (9% of advanced stage serous carcinomas) but distinctive well-differentiated tumor which usually has the appearance of invasive low-grade (micropapillary) serous carcinoma.
  • The rarity of this tumor, however, will require a larger series to demonstrate prognostic value.
  • The potential for confounding of grade with substage, volume of residual disease and patient age are issues that may impede determination of the independence of tumor grade in prognosis, and more data, especially for low-grade tumors, are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828848.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Kanwar VS, Heath J, Krasner CN, Pearce JM: Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy. Pediatr Blood Cancer; 2008 May;50(5):1060-2
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
  • Advanced small cell carcinoma of the ovary (FIGO stage III or IV) is a rare and usually lethal tumor seen in adolescents and young women.
  • In pediatric patients with advanced disease, there have been only two case reports of successful therapy, we report a third patient, diagnosed at 17 years of age, with an abdominal mass and metastatic disease to regional and distant lymph nodes, who was successfully treated with surgery and intensive multi-agent chemotherapy.
  • Imatinib, thalidomide, and celecoxib were also administered for up to 24 months following initial chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Small Cell / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Benzamides. Bleomycin / administration & dosage. Celecoxib. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Imatinib Mesylate. Lymph Nodes / pathology. Lymphatic Metastasis. Piperazines / administration & dosage. Pyrazoles / administration & dosage. Pyrimidines / administration & dosage. Sulfonamides / administration & dosage. Thalidomide / administration & dosage. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17914739.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrazoles; 0 / Pyrimidines; 0 / Sulfonamides; 11056-06-7 / Bleomycin; 4Z8R6ORS6L / Thalidomide; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8A1O1M485B / Imatinib Mesylate; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


25. Ohtani K, Sakamoto H, Masaoka N, Shimada K, Kanaeda T, Kurihara M, Nagai N, Satoh K: A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration. Gynecol Oncol; 2000 Dec;79(3):515-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration.
  • BACKGROUND: Primary squamous cell carcinoma of the ovary is uncommon and has a poor prognosis.
  • Because of its rarity, the effective postoperative treatment is unknown.
  • We describe a remarkable response of this tumor to weekly paclitaxel-carboplatin administration.
  • CASE: A 53-year-old woman had rapidly growing primary squamous cell carcinoma of the ovary that metastasized to the abdominal wall and transverse colon after maximum cytoreductive surgery.
  • The tumor was resistant to primary chemotherapy with cisplatin, vincristine, mitomycin C, and bleomycin.
  • A combination of paclitaxel and carboplatin was used for second-line chemotherapy and was repeated every week.
  • The patient tolerated the chemotherapy well and demonstrated a pathological complete response in the abdominal metastases following the five courses of chemotherapy.
  • CONCLUSION: Weekly paclitaxel-carboplatin administration may be a safe and effective treatment for advanced and rapidly growing ovarian squamous cell carcinoma with primary resistance to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / secondary. Carboplatin / administration & dosage. Colonic Neoplasms / drug therapy. Colonic Neoplasms / secondary. Drug Administration Schedule. Female. Humans. Middle Aged. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11104632.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Reckova M, Mego M, Rejlekova K, Sycova-Mila Z, Obertova Z, Mardiak J: Small-cell carcinoma of the ovary with breast metastases: a case report. Klin Onkol; 2010;23(1):43-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell carcinoma of the ovary with breast metastases: a case report.
  • BACKGROUNDS: Small cell carcinoma (SCC) is characterised by high metastatic potential and the possibility to metastasize to practically any tissue.
  • Small cell carcinoma of the ovary (SCCO) has a very poor prognosis and patients usually die within one year of the initial diagnosis.
  • Considering the clinical presentation, the patient's age, the absence of hypercalcemia and histological characteristics, a diagnosis of pulmonary type SCCO was made.
  • There was no tumour present in the lungs at the time of the initial diagnosis and thus we ruled out pulmonary SCC.
  • RESULTS: Initially, the patient was treated with radiotherapy of the bone lesion and systemic chemotherapy (etoposide with carboplatin) with the result of partial remission.
  • Six months later she was diagnosed with progressive disease in the bone, soft tissue including the breast as well as new lesions in the right kidney, pelvis and lungs.
  • She was treated with 2nd line chemotherapy (topotecan with cisplatin) with the result of progressive disease.
  • CONCLUSION: Extrapulmonary small cell carcinoma is a clinicopathological entity distinct from pulmonary small cell carcinoma.
  • It is very rare and therefore there is very little information available regarding treatment of this disease.
  • In contrast to experience in the treatment of pulmonary small cell cancers, prolonged survival is not common.
  • [MeSH-major] Breast Neoplasms / secondary. Carcinoma, Small Cell / secondary. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192073.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


27. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM: Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol; 2007 May;105(2):404-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
  • OBJECTIVE: Clear cell carcinoma of the ovary is an aggressive tumor characterized by relative chemoresistance and a poor prognosis.
  • The purpose of this study was to review our experience with recurrent clear cell carcinoma of the ovary to evaluate its responsiveness to systemic cytotoxic and hormonal agents.
  • METHODS: All patients diagnosed with clear cell carcinoma of the ovary seen at our institution between 1990 and 2002 were identified and their medical records reviewed.
  • 1) primary diagnosis of clear cell carcinoma of the ovary, 2) measurable recurrent disease, 3) treatment of recurrent disease with 1 or more systemic regimens, and 4) adequate clinical information.
  • RESULTS: Fifty-one patients treated for recurrent clear cell carcinoma were identified.
  • The patients received a total of 105 regimens (344 cycles of therapy).
  • CONCLUSION: Our findings suggest that recurrent clear cell carcinoma of the ovary is particularly chemoresistant.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Drug Resistance, Neoplasm. Female. Humans. Melphalan / administration & dosage. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17292461.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan
  •  go-up   go-down


28. Tomsová M, Melichar B, Sedláková I, Nová M: [Prognostic markers in ovarian carcinoma--retrospective study]. Cesk Patol; 2005 Apr;41(2):51-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic markers in ovarian carcinoma--retrospective study].
  • Ovarian carcinoma is one of the most common cancers in women.
  • The high mortality is due mostly to the fact that the tumour is frequently diagnosed in advanced stages.
  • The aim of our study was to find immunohistochemically detectable significant prognostic markers for invasive ovarian carcinoma.
  • There were two areas of research: the expression of hormonal receptors by tumour cells, and the examination of proliferation activity of the tumour cell by means of antibody Ki-67.
  • Tumour samples from 96 patients with carcinoma of ovary were evaluated (age 27-82 years, mean 55.2 years).
  • Size of residual tumour (p = 0.00002), FIGO stage (p = 0.001), age (p = 0.018), expression of progesterone receptors (p = 0.004), coexpression of steroid receptors (p = 0.039), proliferation activity of the tumour cell (p = 0.04), and chemotherapy (p = 0.018) were significant predictors of survival in univariate analysis.
  • Borderline significance was found in other evaluated parameters: grade (p = 0.063) and histology of carcinoma (p = 0.085).
  • Multivariate analysis revealed that only clinical parameters were significant prognostic factors: size of residual tumor (p < 0.0000), chemotherapy (p = 0.0009), radiotherapy (p = 0.0097), and age (p = 0.0048).
  • [MeSH-major] Carcinoma / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966333.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Receptors, Steroid
  •  go-up   go-down


29. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M: Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol; 2000 Nov;79(2):211-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
  • OBJECTIVES: The aim of this study was to evaluate the ability of paclitaxel to achieve a second clinical response in patients with recurrent epithelial ovarian carcinoma who responded to standard therapy with platinum and paclitaxel in the initial setting.
  • METHODS: Thirty-four patients with epithelial ovarian who demonstrated a complete response to paclitaxel and platinum in the initial treatment setting were retreated with paclitaxel as a single agent for relapse of their disease.
  • CONCLUSION: These results demonstrate that patients with ovarian cancer who relapse after initial treatment with paclitaxel often have disease that is still responsive to the agent.
  • Given its relative lack of cumulative toxicity, retreatment with paclitaxel as a single agent is a reasonable therapeutic option for patients with recurrent ovarian cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Peritoneal Neoplasms / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11063646.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Rana S, Warren BK, Yamada SD: Stage IIIC small cell carcinoma of the ovary: survival with conservative surgery and chemotherapy. Obstet Gynecol; 2004 May;103(5 Pt 2):1120-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IIIC small cell carcinoma of the ovary: survival with conservative surgery and chemotherapy.
  • BACKGROUND: Small cell carcinoma of the ovary is an aggressive tumor primarily affecting young women.
  • Despite adjuvant therapy, the majority of patients described in the literature have fared poorly, even when the disease is diagnosed at an early stage.
  • CASE: A 19-year-old nulligravida with small cell carcinoma of the left ovary underwent conservative surgery with staging and was found to have stage IIIC disease.
  • She received multiagent chemotherapy with vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide and is alive and doing well more than 2 years after completion of her therapy, with no evidence of disease.
  • CONCLUSION: In young patients who desire future fertility, conservative surgery followed by aggressive multiagent chemotherapy may be an effective treatment regimen and warrants further consideration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / therapy. Fallopian Tubes / surgery. Ovarian Neoplasms / therapy. Ovariectomy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Neoplasm Staging. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15121630.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Lin J, Du J, Zhang CY, Xie QT, Zhang B, Liu CR: [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2010 Oct;39(10):655-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
  • OBJECTIVE: To evaluate the two-tier MDACC grading system for ovarian serous carcinoma by comparing with the WHO grading system, and to investigate the role of p53 immunostaining in ovarian serous carcinoma grading.
  • METHODS: 72 cases ovarian serous carcinoma of ovary were graded basing on the MDACC and WHO grading systems, respectively.
  • Neither system has a definite relationship with the disease-free survival time (P=0.170 vs. P=0.075), cytoreduction (P=0.478 vs. P=0.120), and the curative effect of platinum-based chemotherapy (P=0.418 vs. P=0.403).
  • However, compared with the WHO grading system, MDACC grading system has a better correlation with tumor stage (P=0.041 vs. P=0.002), 3-year disease-free survival rate (P=0.077 vs. P=0.004), overall survival time (P=0.080 vs. P=0.046), and p53 immunohistochemistry results (P=0.334 vs. P=0.035).
  • Although p53 immunostaining was valuable in assisting MDACC grading, it should be cautious to use it alone as an independent indicator in predicting the prognosis of ovarian serous carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / metabolism. Disease-Free Survival. Female. Follow-Up Studies. Humans. Membrane Proteins / metabolism. Middle Aged. Neoplasm Staging. Platinum Compounds / administration & dosage. Survival Rate. World Health Organization

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176529.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / MUC16 protein, human; 0 / Membrane Proteins; 0 / Platinum Compounds; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


32. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC: Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol; 2006 Aug;108(2):361-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
  • OBJECTIVE: To analyze the clinical behavior of patients with stage II-IV low-grade serous carcinoma of the ovary seen at our institution who underwent primary surgery followed by platinum-based chemotherapy.
  • METHODS: Patients with stage II-IV low-grade serous carcinoma of the ovary from 1978 to 2003 were identified using existing databases.
  • Response rate to platinum-based chemotherapy in 10 evaluable patients (15% of patients with gross residual disease) was 80%, and 42 patients underwent second-look surgery: microscopically negative findings, 2 (5%); microscopically positive disease, 13 (33%); macroscopically positive disease, 24 (62%); and insufficient information, 3 (7%).
  • Median progression-free survival and overall survival times were 19.5 and 81.8 months.
  • Persistent disease after primary chemotherapy was the only factor associated with shorter overall survival time (hazard ratio 3.46, 95% confidence interval 2.00-5.97, P<.001).
  • CONCLUSION: Metastatic low-grade serous carcinoma of the ovary is characterized by young age at diagnosis and prolonged overall survival.
  • [MeSH-major] Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / therapy. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Texas / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880307.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Marsden DE, Friedlander M, Hacker NF: Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol; 2000 Jul-Aug;19(1):11-9
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of epithelial ovarian carcinoma: a review.
  • Epithelial carcinoma of the ovary is the most lethal of gynaecological malignancies and it affects about one in 70 women in developed countries.
  • Over 75% of women with the disease have tumour spread beyond the pelvis at the time of diagnosis, and their treatment requires the appropriate use of surgery and chemotherapy.
  • The strategies used in the treatment of ovarian cancer are constantly evolving.
  • An overview of current treatment regimens and their evolution is provided, with particular emphasis on the interdependence of surgery and chemotherapy in the optimal management of the disease.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / blood. Chemotherapy, Adjuvant. Female. Humans. Laparotomy. Lymph Node Excision. Neoplasm Recurrence, Local. Neoplasm Staging. Platinum Compounds / therapeutic use. Reoperation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10883019.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Platinum Compounds
  • [Number-of-references] 127
  •  go-up   go-down


34. Pautier P, Ribrag V, Duvillard P, Rey A, Elghissassi I, Sillet-Bach I, Kerbrat P, Mayer F, Lesoin A, Brun B, Crouet H, Barats JC, Morice P, Lhommé C: Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. Ann Oncol; 2007 Dec;18(12):1985-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type.
  • BACKGROUND: The evaluation of first-line intensive combination therapy in small cell carcinoma of the ovary (SCCO).
  • PATIENTS AND METHODS: Debulking surgery; four to six cycles of chemotherapy with cisplatin (P) 80 mg/m(2) day 1, adriamycin (A) 40 mg/m(2) day 1, vepeside (V) 75 mg/m(2)/day days 1-3, cyclophosphamide (EP) 300 mg/m(2)/day days 1-3, every 3 weeks and granulocyte colony-stimulating factor with, in case of a complete remission, high-dose chemotherapy with carboplatin, vepeside, cyclophosphamide and stem-cell support.
  • Eight patients progressed under chemotherapy.
  • Among 18 patients in complete response (CR), 10 received high-dose chemotherapy (CT) (three stem-cell collection failures, two protocol violations, two disease progression and one refusal).
  • CONCLUSIONS: Initial dose-intensive therapy achieves interesting overall survival in SCCO.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761699.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Zhang P, Feng FY, Wu LY, Hu Y, Liu JW, Gao YJ, Guan XQ, Nan KJ, Suo AL, Wang XW, Zhang MH, Zhang WD, Li CW, Zhang Y, Zhao JB: [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors]. Zhonghua Zhong Liu Za Zhi; 2006 Mar;28(3):230-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
  • OBJECTIVE: To evaluate and compare the efficacy and safety of Nedaplatin (NDP)-based regimen and cisplatin (DDP)-based regimen for head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal cancer and ovary epithelial cell carcinoma.
  • Combination chemotherapy group: combined with 5-Fu, NVB, VDS + 5-Fu, PTX or CTX respectively, NDP 80 mg/m(2) on D1 or DDP 30 mg/m(2) on D1-3, every 3 weeks for at least 2 cycles was given.
  • The response rate of single Nedaplatin chemotherapy for advanced NSCLC was 10.5% (2/19), for ovary carcinoma (1/3) and HNSCC (1/1).
  • For NSCLC and ovary carcinoma patients who had failed in the previous DDP-based chemotherapy, the response rates by single NDP chemotherapy were still 9.1% and 33.3%.
  • The response rate of NDP-based combination regimen for NSCLC, ovary carcinoma, HNSCC and esophageal cancer was 33.9% (21/62), 44.8% (13/29), 20.0% (3/15) and 18.2% (4/22), respectively, which was not statistically different from the rate of controlled group treated by DDP-based regimen.
  • CONCLUSION: Nedaplatin is effective in the treatment for HNSCC, NSCLC and ovary carcinoma.
  • Compared with the control group treated by DDP-based regimen, nedaplatin-based combination chemotherapy has similar effect on HNSCC, NSCLC, ovary carcinoma and esophageal cancer.
  • Gastrointestinal reaction of nedaplatin is milder than that of cisplatin but the liver function during chemotherapy must be monitored closely.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Head and Neck Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Esophageal Neoplasms / drug therapy. Female. Fluorouracil / administration & dosage. Humans. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Middle Aged. Nausea / chemically induced. Ovarian Neoplasms / drug therapy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875614.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 5V9KLZ54CY / Vinblastine; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Manchana T, Ittiwut C, Mutirangura A, Kavanagh JJ: Targeted therapies for rare gynaecological cancers. Lancet Oncol; 2010 Jul;11(7):685-93
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for rare gynaecological cancers.
  • Some gynaecological cancers are uncommon, such as sex cord-stromal tumours, malignant germ-cell tumours, vulvar carcinoma, melanoma of the female genital tract, clear-cell carcinoma of the ovary and endometrium, neuroendocrine tumours of the cervix, and gestational trophoblastic neoplasia.
  • Despite aggressive treatment, some cancers recur or respond poorly to therapy.
  • Comprehensive knowledge of the molecular biology of each cancer might help with development of novel treatments that maximise efficacy and minimise toxic effects.
  • Targeted therapy is a new treatment strategy that has been investigated in various tumours in clinical and laboratory settings.
  • Novel targeted agents either alone or in combination with other treatments offer promising therapeutic options.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems / trends. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Female. Gestational Trophoblastic Disease / drug therapy. Humans. Melanoma / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Neuroendocrine Tumors / drug therapy. Pregnancy. Sex Cord-Gonadal Stromal Tumors / drug therapy. Vulvar Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20362508.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 77
  •  go-up   go-down


37. Christin A, Lhomme C, Valteau-Couanet D, Dubrel M, Hartmann O: Successful treatment for advanced small cell carcinoma of the ovary. Pediatr Blood Cancer; 2008 Jun;50(6):1276-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for advanced small cell carcinoma of the ovary.
  • Small cell carcinoma of the ovary is a rare and aggressive malignant tumour with a poor prognosis.
  • They were treated with surgical resection, multiagent chemotherapy and high-dose chemotherapy followed by autologous bone marrow transplantation.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18293381.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Modares Gilani M, Karimi Zarchi M, Behtash N, Ghaemmaghami F, Mousavi AS, Behnamfar F: Preservation of pregnancy in a patient with advanced ovarian cancer at 20 weeks of gestation: case report and literature review. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1140-3
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To report a case of FIGO stage III papillary serous carcinoma of ovary, diagnosed during pregnancy at 20 weeks of gestation and treated with unilateral salpingo-oophorectomy and surgical staging, then initial combination chemotherapy while preserving the pregnancy.
  • The patient underwent three postoperative courses of chemotherapy (carboplatin plus paclitaxel regimen).
  • Combination chemotherapy during pregnancy with preservation of the fetus could be considered, and should be discussed with caution in case of epithelial ovarian cancer diagnosed during the second trimester of the pregnancy.
  • [MeSH-major] Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy, High-Risk
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Infant, Newborn. Live Birth. Male. Pregnancy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433066.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


39. Amanti C, Lombardi A, Moscaroli A, Catracchia V, Lo Russo M, Marino G, Conte S, Provenza G: [Peritoneal papillary serous carcinoma in a patient with previous surgery for breast cancer: clinical case]. G Chir; 2006 Jan-Feb;27(1-2):45-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal papillary serous carcinoma in a patient with previous surgery for breast cancer: clinical case].
  • [Transliterated title] [Carcinoma sieroso papillare del peritoneo in paziente già operata di carcinoma mammario. Caso clinico]
  • The peritoneal papillary serous carcinoma (PPSC) is a rare tumor more frequently revealed in female.
  • It implicate peritoneum, ovary's surface and pelvis.
  • The histology of this disease is similar to papillary serous carcinoma ovary (PSCO).
  • The cytoreductive surgery and the cisplatinum chemotherapy, and other treatments like immunotherapy and radiotherapy, increase the PSCP patient survival.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608633.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


40. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol; 2002 Aug;100(2):281-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.
  • OBJECTIVE: To estimate whether and how the biologic behavior of clear cell carcinoma contributes to the chemoresistance mechanism.
  • METHODS: Forty-one patients with clear cell carcinoma and 90 patients with serous adenocarcinoma, who had measurable disease after initial surgery, were examined.
  • All patients underwent cytoreductive surgery followed by platinum-based chemotherapy.
  • RESULTS: The 5-year survival rate for patients with clear cell carcinoma was significantly poorer, compared with serous adenocarcinoma (20.0% versus 31.9%).
  • Response rate to chemotherapy was 14.6% for clear cell carcinoma and 72.2% for serous adenocarcinoma.
  • The expression of P-glycoprotein and multidrug resistance-associated protein did not differ between responders and nonresponders in both tumor types.
  • The Ki-67 labeling index (LI) in clear cell carcinoma was significantly lower than serous adenocarcinoma (18.4% versus 38.8%).
  • The LI for responders was significantly higher than that for nonresponders in both tumor types.
  • In clear cell carcinoma, the mean value of LI was 15.3% for nonresponders, but that for responders was 30.2%, which was similar to that for serous adenocarcinoma.
  • Multivariable analysis revealed that LI and residual tumor size were the independent prognostic factors.
  • CONCLUSION: Lower proliferation of tumor may be a behavior of clear cell carcinoma of the ovary that contributes to its resistance to chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Resistance, Multiple. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Division / drug effects. Cell Division / physiology. Chemotherapy, Adjuvant. Cohort Studies. Confidence Intervals. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Multivariate Analysis. Neoplasm Staging. Ovariectomy / methods. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12151151.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


41. Lambert HE, Gregory WM, Nelstrop AE, Rustin GJ: Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer; 2004 Sep-Oct;14(5):772-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population.
  • The objective was to assess the long-term survival (5-15 years) in 463 women, with stages IIb-IV epithelial carcinoma of the ovary and to compare their survival with that of a normal population matched for age and sex.
  • Statistical analysis of 463 women, with stages IIb-IV epithelial cancer of the ovary, who were participants in two consecutive North Thames Ovary Group randomized trials, which took place between 1985 and 1994, was performed.
  • The women were treated with debulking surgery, where possible, and adjuvant platinum chemotherapy.
  • The important prognostic factors for long-term survival were disease-free or minimal residual disease (a single remaining deposit <2 cm) at initial surgery with tumor grade 1 and good performance status.
  • Compared with the normal population (1995 data), the ratio of observed to expected deaths after start of chemotherapy at 5 years was 14.1 (P < 0.001 Fisher's exact test), at 9-10 years 4.9 (P = 0.0033, Fisher's exact test), while in the 11- to 15-year period it had dropped to 2.75 (P = 0.090, Fisher's exact test), which was not significantly different.
  • Patients with advanced cancer of the ovary, who survive 11 years or longer, have a life expectancy which is very similar to that of a normal population of women of the same age.
  • Women with advanced ovarian cancer have an improved chance of long-term survival following treatment if they present with minimal residual disease after primary surgical debulking, grade 1 tumors, and good performance status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361183.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Lou HM, Lou HK, Wu MJ: [Synchronous primary cancer of the endometrium and ovary]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):617-20
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancer of the endometrium and ovary].
  • To investigate the clinical and pathological characteristics, treatment, and The data of 12 patients prognosis of synchronous primary cancer of the endometrium and ovary.
  • Methods with synchronous primary cancer of the endometrium and ovary were retrospectively reviewed .
  • Results Eight patients had the same histological type of endometrioid carcinoma in both uterus and ovary, 4 patients had different histological types in uterus and ovary.
  • Synchronous primary cancer of the endometrium and ovary was difficult to be dignosed preoperatively.
  • endometrioid carcinomas was the main pathologic type (66.7%).
  • All patients were treated surgically followed by chemotherapy with a 3-year survival rate of 66.7% (8/12).
  • CONCLUSION: Synchronous primary endometrium and ovary cancer is a specific kind of tumor different from either the primary endometrium carcinoma or ovary carcinoma, and usually can be detected in early stage with a good prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236559.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol
  •  go-up   go-down


43. Zhang Y, Yang JX, Wu M, Shen K: [Clinicopathological conference: an advanced ovarian carcinoma patient suddenly died of pulmonary embolism]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug;25(4):471-5
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological conference: an advanced ovarian carcinoma patient suddenly died of pulmonary embolism].
  • Stage IIIc, grade 2 clear cell carcinoma of the ovary was diagnosed after laparotomy.
  • Weekly paclitaxel combined with carboplatin as adjuvant chemotherapy was given after optimal cytoreductive surgery.
  • An acute cerebral infarction after first chemotherapy cycle was developed.
  • The patient presented with dyspnoea after the third chemotherapy cycle and the symptom could be relieved at rest.
  • Autopsy revealed ovarian clear cell carcinoma with metastasis to the whole pelvic and abdominal cavity and massive pulmonary arterial embolism (the length of embolus is 20 cm) with cerebral infarction.
  • A conclusive remarks was made during the conference that patients who underwent operation and chemotherapy were at high risk for venous thrombosis (VT) and pulmonary embolism (PE).

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12974096.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] Clinical Conference; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


44. Trojan J, Ly A, Wei MX, Bierwagen M, Kopinski P, Pan Y, Ardourel MY, Dufour T, Shevelev A, Trojan LA, François JC, Andres C, Popiela T, Chatel M, Kasprzak H, Anthony DD, Duc HT: Antisense anti IGF-I cellular therapy of malignant tumours: immune response in cancer patients. Biomed Pharmacother; 2010 Oct;64(8):576-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense anti IGF-I cellular therapy of malignant tumours: immune response in cancer patients.
  • The treatment of cancer by antisense anti-IGF-I cellular therapy inducing immune response has evoked interest among many promising strategies.
  • Here, we reported some results obtained from patients with cancer, mainly glioblastoma treated by this strategy, which was also extended to patients with colon carcinoma, ovary cystadenocarcinoma and prostate adenocarcinoma.
  • It was shown that, in the phase I of clinical trial, patients vaccinated with their own tumour cells treated by antisense IGF-I presented a slight increase of temperature.
  • Particularly, in two treated patients with glioblastoma, the survival time was 19 and 24 months respectively in comparison to the range of 12 to 15 months observed in the case of classical treatment such as surgery, radiation or chemotherapy.
  • Furthermore, the increase in the percentage of peripheral blood monomorphonucleated cells (PBMNCs) with effector phenotype, i.e., CD8+ CD28+ in vaccinated patients might explain their prolonged survival time.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Insulin-Like Growth Factor I / genetics. Neoplasms / therapy. RNA, Antisense / genetics. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20630696.001).
  • [ISSN] 1950-6007
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Antigens, CD28; 0 / Antigens, CD8; 0 / Cancer Vaccines; 0 / ITGAM protein, human; 0 / RNA, Antisense; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


45. Nappi L, Indraccolo U, Matteo M, Rosenberg P, Greco P: Malignant mixed müllerian tumor of the fallopian tube coincident with a primary serous carcinoma of the ovary. Case report. Eur J Gynaecol Oncol; 2007;28(6):511-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor of the fallopian tube coincident with a primary serous carcinoma of the ovary. Case report.
  • Malignant mixed müllerian tumors are very rare neoplasms of the fallopian tube, and treatment is not well defined.
  • A case of malignant mixed müllerian tumor of the tube concomitant with a primary serous carcinoma of the ovary is reported.
  • It was unclear if there were two distinct neoplasms in the same patient, or if it was a single tumor with a sarcomatous fallopian conversion of the serous component, as described for some recurrent ovarian carcinomas.
  • Chemotherapy for ovarian carcinoma with intraperitoneal metastasis was performed, with about a three-year interval-free period of disease, as could be expected for ovarian carcinomas at the same stage.
  • Therapy for the very rare cases similar to the one reported here needs to be improved.
  • [MeSH-major] Fallopian Tube Neoplasms / complications. Mixed Tumor, Mullerian / complications. Ovarian Neoplasms / complications

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179150.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC: Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol; 2006 Jul;102(1):5-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bevacizumab has demonstrated activity against a variety of solid tumors, including ovarian carcinoma.
  • CASES: One patient each with recurrent, refractory well-differentiated serous-endometrioid ovarian carcinoma, micropapillary serous carcinoma of the ovary, and primary peritoneal micropapillary serous carcinoma were treated with single agent bevacizumab (15 mg/kg [DOSAGE ERROR CORRECTED] intravenously every 3 weeks).
  • CONCLUSION: Bevacizumab may have significant activity against well-differentiated ovarian carcinoma and micropapillary serous carcinomas of the ovary or peritoneum.
  • Since these tumors are generally indolent and not responsive to adjuvant therapy, further investigation is warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Gynecol Oncol. 2007 May;105(2):559. dosage error in text
  • (PMID = 16697451.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


47. Edgerton CC, Gilman M, Roth BJ: Topotecan-induced bronchiolitis. South Med J; 2004 Jul;97(7):699-701
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topotecan HCl is an antitumor drug exhibiting topoisomerase 1-inhibitory activity.
  • Topotecan is used in the treatment of metastatic carcinoma of the ovary and as second-line treatment of small-cell lung cancer.
  • [MeSH-minor] Carcinoma / drug therapy. Female. Humans. Middle Aged. Peritoneal Neoplasms / drug therapy. Topotecan / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15301130.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


48. Wong TM, Yeo W, Chan LW, Mok TS: Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature. Gynecol Oncol; 2000 Feb;76(2):223-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hemorrhagic cystitis is a well-known complication of cyclophosphamide therapy but extensive involvement of the entire urinary tract is far less common.
  • We report here a patient who developed severe hemorrhagic pyelitis, ureteritis, and cystitis after one cycle of cyclophosphamide-containing combination chemotherapy.
  • METHOD: A patient with synchronous carcinoma of the ovary and the uterus developed severe hemorrhagic pyelitis, ureteritis, and cystitis leading to bilateral hydronephroses and acute renal failure after one cycle of combination chemotherapy containing cyclophosphamide.
  • [MeSH-minor] Carcinoma, Endometrioid / drug therapy. Cystadenocarcinoma, Serous / drug therapy. Endometrial Neoplasms / drug therapy. Female. Humans. Middle Aged. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10637075.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


49. Sant'Ambrogio S, Malpica A, Schroeder B, Silva EG: Primary ovarian rhabdomyosarcoma associated with clear cell carcinoma of the ovary: a case report and review of the literature. Int J Gynecol Pathol; 2000 Apr;19(2):169-73
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian rhabdomyosarcoma associated with clear cell carcinoma of the ovary: a case report and review of the literature.
  • The clinicopathologic and immunohistochemical findings of a case of coexistent primary ovarian rhabdomyosarcoma and clear cell carcinoma of the ovary are reported.
  • The tumor was detected in a 41-year-old premenopausal woman who had a 1-year history of pelvic pain.
  • The tumor was composed of solid and cystic areas, and two distinct microscopic components were identified: clear cell carcinoma and rhabdomyosarcoma.
  • Despite two cycles of chemotherapy, the disease persisted in the pelvis 4 months after diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782415.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / Myoglobin
  • [Number-of-references] 13
  •  go-up   go-down


50. Dernedde U, Dernedde R, Shepstone L, Barrett A: Three-year single institution audit on transfusion requirements in oncology patients. Clin Oncol (R Coll Radiol); 2007 May;19(4):223-7
MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Data from hospital-based sources were condensed in a single spread sheet covering 1611 transfusions of a total of 881 patients together with data on 25,264 treatment sessions in 6137 patients within a time period between 1 August 2001 and 31 July 2004.
  • This was accompanied by an increased threshold for transfusions, as shown by a significant rise in mean haemoglobin trigger levels from 8.53 to 8.86 g/dl (P<0.001) as well as an increase in treatment sessions and patient numbers - especially for chemotherapy or combinations of chemotherapy and radiotherapy.
  • The highest transfusion rates and also the greatest increments occurred in patients with carcinoma of the ovary, lung and pancreas.
  • Within these groups, treatment regimens as well as treatment lines were additional predictive factors.
  • [MeSH-major] Anemia / therapy. Blood Transfusion / economics. Blood Transfusion / utilization. Health Services Needs and Demand. Hospitals, University / utilization. Utilization Review
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Breast Neoplasms / complications. Breast Neoplasms / therapy. Cost-Benefit Analysis. Database Management Systems. England. Erythropoietin / therapeutic use. Female. Hemoglobins / analysis. Humans. Lung Neoplasms / complications. Lung Neoplasms / therapy. Male. Medical Audit. Medical Oncology. Ovarian Neoplasms / complications. Ovarian Neoplasms / therapy. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / therapy. Radiation Oncology

  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433967.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins; 11096-26-7 / Erythropoietin
  •  go-up   go-down


51. Giblin J, Fanucchi MP, McGuire WP: Clear cell carcinoma of the ovary: a remarkable case. Am J Clin Oncol; 2001 Feb;24(1):99-100
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the ovary: a remarkable case.
  • Clear cell carcinoma of the ovary is uncommon, and there are few reports of successful long-term therapy.
  • In this case report, a previously healthy preadolescent presented with clear cell carcinoma of the ovary.
  • After progressing through two regimens of chemotherapy, she was given topotecan, which arrested the disease.
  • Our treatment plan is to continue to administer this therapy at monthly intervals until relapse.
  • Although the achievement of stable disease with topotecan is frequently observed in patients relapsing with epithelial ovarian cancer, durable stable disease in clear cell carcinoma of the ovary is unusual.
  • Treatment--and long-term maintenance therapy--with topotecan may be an option in such patients.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Quality of Life. Topotecan / therapeutic use

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11232961.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


52. Ardavanis A, Karamouzis MV, Alexopoulos A, Rigatos G: Simultaneous endometrioid ovarian and uterine carcinoma diagnosed after an in vitro fertilization procedure--case report and review of the literature. Eur J Gynaecol Oncol; 2005;26(6):654-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous endometrioid ovarian and uterine carcinoma diagnosed after an in vitro fertilization procedure--case report and review of the literature.
  • BACKGROUND: The presence of simultaneous carcinomas involving both the ovary and uterus is relatively uncommon, while the possible link between fertility drugs and carcinogenesis still remains controversial.
  • CASE: The case of a 40-year-old patient with simultaneous aggressive endometrioid carcinoma of the ovary and uterus a few months after the sixth attempt of in vitro fertilization is presented.
  • The patient had de novo lung disease at surgery and diffuse metastatic spread to adjacent bone, subcutaneous tissue and the central nervous system (CNS) soon after a spectacular response to the primary paclitaxel/carboplatinum chemotherapy and while on maintenance and second-line chemotherapy, respectively.
  • Definite conclusions about the possible association with the previously performed assisted reproduction cannot be drawn but close clinical surveillance of such patients before, during and after infertility treatment is strongly warranted.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Fertilization in Vitro / adverse effects. Lung Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Female. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398231.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 16
  •  go-up   go-down


53. Ryu DR, Yoo TH, Kim YT, Jeong HJ, Cho NH, Kang SW: Minimal change disease in a patient with ovarian papillary serous carcinoma. Gynecol Oncol; 2004 May;93(2):554-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal change disease in a patient with ovarian papillary serous carcinoma.
  • BACKGROUND: Nephrotic syndrome (NS) is rarely associated with ovarian tumor.
  • However, the association between minimal change disease (MCD) and ovarian tumor has not been previously reported.
  • Radiologic studies revealed a 10 x 10 x 11 cm-sized mass and multiple enlarged lymph nodes, suggesting a malignant ovarian tumor.
  • Histopathology of the mass and the kidney revealed papillary serous carcinoma of the ovary and MCD, respectively.
  • Oral prednisolone and adjuvant chemotherapy resulted in remission of NS.
  • CONCLUSION: We herein report a case of MCD associated with ovarian carcinoma.

  • Genetic Alliance. consumer health - Minimal change disease.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15099980.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Maranhão RC, Graziani SR, Yamaguchi N, Melo RF, Latrilha MC, Rodrigues DG, Couto RD, Schreier S, Buzaid AC: Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother Pharmacol; 2002 Jun;49(6):487-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We had previously shown in acute leukemia and in breast and ovary carcinoma patients that a cholesterol-rich emulsion (LDE) that binds to receptors for low-density lipoprotein (LDL) may concentrate in neoplastic tissues.
  • In this study, the potential of LDE as a carrier for anticancer drugs was investigated.
  • The plasma kinetics of the complex and its uptake by tumor and normal tissue were determined in cancer patients.
  • Finally, an exploratory clinical study to determine the toxicity profile of LDE-carmustine at escalating dose levels was conducted in 42 advanced cancer patients refractory to conventional chemotherapy.
  • The pharmacological action of carmustine, as tested in cancer cells, was not diminished by association with LDE compared with the free drug and was indeed mediated by the LDL receptor.
  • The biodistribution in mice and plasma kinetics in patients of the emulsion were not changed by association of the drug.
  • The uptake of LDE-carmustine by tumor was severalfold greater than the uptake by the corresponding normal tissue.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Carmustine / administration & dosage. Drug Carriers. Lipids. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Animals. Cell Survival / drug effects. Emulsions. Female. Humans. In Vitro Techniques. Mice. Middle Aged. Nausea / chemically induced. Pilot Projects. Thrombocytopenia / chemically induced. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12107554.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Drug Carriers; 0 / Emulsions; 0 / Lipids; U68WG3173Y / Carmustine
  •  go-up   go-down


55. Swiersz LM: Role of endometriosis in cancer and tumor development. Ann N Y Acad Sci; 2002 Mar;955:281-92; discussion 293-5, 396-406
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of endometriosis in cancer and tumor development.
  • In spite of these similarities, endometriosis is not considered a malignant disorder.
  • Mutations in the genes that encode for metabolic and detoxification enzymes, such as GALT and GSTM, have been implicated in the pathogenesis of endometriosis and in the progression to carcinoma of the ovary.
  • PTEN, a tumor suppressor commonly mutated (50%) in endometrial carcinoma, is found mutated in endometrioid carcinoma of the ovary, but not in other forms of ovarian cancer.
  • A recent study has shown that somatic mutations in the PTEN gene were identified in 20% of endometrioid carcinomas and 20.6% of solitary endometrial cysts, suggesting that inactivation of the PTEN tumor suppressor gene is an early event in the development of ovarian endometrioid carcinoma.
  • In addition to cancerous transformation at the site of endometriosis, there is recent evidence to indicate that having endometriosis itself may increase a woman's risk of developing non-Hodgkin's lymphoma, malignant melanoma, and breast cancer.
  • [MeSH-major] Breast Neoplasms / etiology. Endometriosis / complications. Melanoma / drug therapy. Ovarian Neoplasms / etiology


56. Umezu T, Shibata K, Shimaoka M, Kajiyama H, Yamamoto E, Ino K, Nawa A, Senga T, Kikkawa F: Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo. Cancer Sci; 2010 Jan;101(1):143-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo.
  • We report here that GPC3 was expressed in clear cell carcinoma of the ovary, and not in other carcinomas.
  • We show that the clear cell carcinoma cell line with silenced GPC3 expression (GPC3 [-]) was more sensitive to paclitaxel than GPC3 (+) cells.
  • These results indicate that increased GPC3 expression in a clear cell carcinoma cell line may play a protective role against apoptosis, and so the downregulation of GPC3 may be a potential target to increase sensitivity to paclitaxel-induced apoptosis in clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Apoptosis / drug effects. Glypicans / antagonists & inhibitors. Ovarian Neoplasms / drug therapy. Paclitaxel / pharmacology
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Female. Gene Silencing. Humans. Mice. Molecular Sequence Data

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860840.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glypicans; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


57. Ma SK, Zhang HT, Wu LY, Liu LY: [Prognostic analysis of 88 patients with ovarian clear cell carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):784-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
  • OBJECTIVE: To investigate the clinical characteristics of clear cell carcinoma of the ovary and to compare the survival of the patients treated by three different chemotherapy regimens.
  • METHODS: Between 1984 and 2005, the clinical data of 88 surgically treated patients with clear cell carcinoma of the ovary were retrospectively analyzed.
  • Of the 88 patients, 55 (62.5%) had tumor in stage I, 2 in stage II, 22 in stage II, 3 in stage IV and 6 in indefinite stage.
  • All patients were given postoperative chemotherapy, 43 patients received CAP/CP, 33 paclitaxel combination with carboplatinum/cisplatin (TC/TP) and 12 CPT-11 plus MMC.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms. Ovariectomy / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396695.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


58. Akbulut M, Zekioglu O, Terek MC, Ozdemir N: Chondromatous differentiation in clear cell carcinoma of the ovary: a rare finding challenging the differential diagnosis. Arch Gynecol Obstet; 2008 Dec;278(6):569-72
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondromatous differentiation in clear cell carcinoma of the ovary: a rare finding challenging the differential diagnosis.
  • OBJECTIVE: Ovarian surface epithelial tumors rarely have heterologous elements including bone or cartilage that may appear histologically benign or malignant.
  • CASE: We report a clear cell carcinoma of the bilateral ovary showing chondromatous differentiation in a 56-year-old woman.
  • Histopathologic study of the specimen showed clear cell carcinoma with many small foci of chondromatous differentiation.
  • The patient was alive with disease on chemotherapy for 16 months.
  • CONCLUSION: A rare case of benign appearing chondromatous differentiation in an ovarian clear cell carcinoma of the ovary is described, and the significance of this finding is discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343935.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Vaughn DJ, Rizzo TA, Malkowicz SB: Chemosensitivity of malignant ovarian-type surface epithelial tumor of testis. Urology; 2005 Sep;66(3):658
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensitivity of malignant ovarian-type surface epithelial tumor of testis.
  • Malignant ovarian-type surface epithelial tumors of the testis and paratestis are rare neoplasms.
  • We report a patient with metastatic disease with demonstrated responsiveness to chemotherapy treatments used in advanced ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Paclitaxel / therapeutic use. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140110.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


60. Balat O, Aydin A, Camci C, Kutlar I, Büyükberber S: Bilateral primary squamous cell carcinoma of the ovary: a case report of isolated metastasis to the lateral pelvic wall. Eur J Gynaecol Oncol; 2001;22(6):445-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral primary squamous cell carcinoma of the ovary: a case report of isolated metastasis to the lateral pelvic wall.
  • Primary squamous cell carcinoma of the ovary is rare.
  • The majority of cases arise most commonly from the lining of a dermoid cyst, and less often in endometriosis or a Brenner tumor.
  • A 40-year-old woman underwent exploratory laparotomy and was found to have a right ovarian tumor adherent to the lateral pelvic wall with no ascites.
  • She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, pelvic lymphadenectomy, infracolic omentectomy, appendectomy, and right nephrectomy for bilateral primary squamous cell carcinoma of the ovary.
  • She was started on multiagent chemotherapy.
  • To our knowledge in this report we present the first case in the English literature of bilateral pure squamous cell carcinoma of the ovary.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874078.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


61. Lee SH, Kim J, Kim JH, Lee KH, Park JS, Hur SY: Malignant mixed mullerian tumor of the cervix including components of a rhabdomyosarcoma: case report and literature review. Eur J Gynaecol Oncol; 2010;31(4):462-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumor of the cervix including components of a rhabdomyosarcoma: case report and literature review.
  • Malignant mixed mesodermal tumors (MMMTs) are composed of carcinomatous and sarcomatous components and have an aggressive metastatic potential, resulting in a poor prognosis.
  • MMMTs of gynecologic origin typically arise from either the ovary or the uterus, and MMMTs of the cervix are extremely rare.
  • Due to the rarity of MMMTs arising from the cervix, there is no consensus regarding treatment, prognosis, and outcome; however, aggressive surgical cytoreduction, combined with adjuvant platinum-based chemotherapy and/or radiotherapy, is recommended as the treatment of choice for MMMTs of the cervix.
  • Cervical MMMTs are more often confined to the uterus at the time of diagnosis and frequently have non-glandular epithelial components.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Rhabdomyosarcoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882897.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


62. Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A: Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug. Cancer Chemother Pharmacol; 2002 Aug;50(2):95-103
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
  • Amongst the analogues which were synthesized to improve both therapeutic index and antitumor activity, the most active ones were those esterified on the 9-OH group such as S 30972-1, the glutaric acid monoester derivative.
  • PURPOSE: To compare the pharmacological profile of S 30972-1 and S 16020-2 in vitro and in vivo and to investigate whether S 30972-1 could act as a prodrug of S 16020-2.
  • RESULTS: Although tumor cell proliferation and accumulation of cells in the G2 phase of the cell cycle were similarly affected by the two compounds after a continuous exposure (IC50 values of 30-50 n M), S 30972-1 was about tenfold less potent than S 16020-2 after short exposures.
  • In vivo, S 30972-1 induced more long-term survivors than S 16020-2 among mice with Lewis lung carcinoma and sensitive or multidrug resistant P388 leukemias.
  • The growth of Colon 38 carcinoma was slightly more inhibited by S 30972-1 than S 16020-2.
  • In the more relevant human orthotopic models, using the optimal doses of each drug, 160 mg/kg S 30972-1 was significantly more active than 80 mg/kg S 16020-2 in the NCI-H460 lung carcinoma.
  • The two compounds were significantly active in A549 lung carcinoma, moderately active in the NIH:OVCAR-3 ovary carcinoma and inactive in the NCI-H125 lung and DU145 prostate carcinomas.
  • CONCLUSIONS: The in vivo profile of these two compounds appeared very similar, although S 30972-1 exhibited globally a wider therapeutic index.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Animals. Animals, Congenic. Carcinoma, Lewis Lung / drug therapy. Carcinoma, Lewis Lung / enzymology. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / enzymology. Cell Cycle / drug effects. Cell Division / drug effects. Drug Screening Assays, Antitumor. Female. Humans. Leukemia P388 / drug therapy. Leukemia P388 / enzymology. Lung Neoplasms / drug therapy. Lung Neoplasms / enzymology. Male. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Inbred DBA. Mice, Nude. Mice, SCID. Organ Specificity. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / enzymology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / enzymology. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172972.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ellipticines; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / Prodrugs; 0 / S 16020-2; 0 / S30972-1; 0 / Topoisomerase II Inhibitors; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


63. Wei CF, Hwang SH, Ho CM, Shih BY, Chien TY: Malignant mixed müllerian tumors of the ovary. Zhonghua Yi Xue Za Zhi (Taipei); 2000 Apr;63(4):344-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumors of the ovary.
  • Malignant mixed Müllerian tumor (MMMT) of the ovary is very rare, and to the best of our knowledge, only a few cases have been reported in the literature from Taiwan.
  • Case 1 was a 59-year-old female with stage IIIC MMMT of the ovary, with a tumor having carcinomatous and sarcomatous elements.
  • The carcinomatous component was composed of a high-grade epithelial malignancy including serous, endometrioid, clear cell and undifferentiated carcinoma elements.
  • The sarcomatous component was composed of a homologous malignant mesenchymal element with conspicuous hyaline globules.
  • The carcinomatous component was composed of grade II-III clear cell carcinoma and the sarcomatous component was composed of high-grade non-specific spindle cell sarcoma, which was positive for vimentin, but negative for cytokeratin, desmin and S-100 protein on immunostaining.
  • These two patients both underwent hysterectomy, bilateral salpingo-oophorectomy and omentectomy and both received platinum-based chemotherapy after debulking surgery.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10820916.001).
  • [ISSN] 0578-1337
  • [Journal-full-title] Zhonghua yi xue za zhi = Chinese medical journal; Free China ed
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi (Taipei)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] CHINA
  •  go-up   go-down


64. Zurabiani TA, Charkviani LI, Gersamia GK: [Treatment of malignant ovarian tumours in Georgia in 1990-2000]. Georgian Med News; 2006 Aug;(137):28-31
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of malignant ovarian tumours in Georgia in 1990-2000].
  • The adequate treatment of ovary tumor and the issue of improvement of subsequent results still remain the urgent question of oncology.
  • Our aim is to study the effectiveness of treatment of malignant ovary tumor based on the data of 1990-2000 provided by A.
  • Gvamichava National Oncological Centre, to develop optimal methods of treatment and select the right tactics in order to improve subsequent results for patients with malignant ovary tumor.
  • The research revealed that the epithelial neoplasm (malignant ovary tumor) is 5.2 times more spread than nonepithelial (malignant ovary tumor).
  • In our clinic the preference is given to the operational method combined with further chemotherapy (ch/t) for treatment of malignant ovary tumor.
  • The number of radical surgery of epithelial neoplasm 3 times exceeds less radical surgery and 12 times--non-radical surgery, while in the case of non epithelial neoplasm the number of radical surgery is two times more than less radical surgery and 3 times more than that non radical.
  • In 1990-2000 in the National Oncological Centre ch/t without platinum and audrioblastin (44.8%) had been most frequently used for treatment of ovary tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. Fluorouracil / administration & dosage. Georgia (Republic). Humans. Hysterectomy. Methotrexate / administration & dosage. Ovariectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980738.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


65. Kommoss F, Kommoss S, Eichhorn J, Schmidt D: [Transitional cell carcinoma of the ovary. Morphological and clinical features]. Pathologe; 2007 May;28(3):209-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transitional cell carcinoma of the ovary. Morphological and clinical features].
  • Transitional cell carcinoma of the ovary (TCC-O) is a less common type of malignant surface epithelial-stromal tumor of the ovary, still with uncertain incidence.
  • Histologically, TCC-O resembles urothelial carcinoma of the urinary system, and by definition does not contain a Brenner tumor component.
  • TCC-O may not be a bona fide urothelial neoplasm, however, but rather a lesion of the Müllerian type derived from the ovarian surface epithelium.
  • This notion is supported by the existence of mixed tumors consisting of TCC-O and other histological types of ovarian carcinoma, as well as the observation that TCC-O has a Müllerian type but not a urothelial-like immunohistochemical profile.
  • Besides metastatic urothelial carcinoma of the urinary tract, the other types of ovarian carcinoma, as well as sex cord-stromal tumors such as adult granulosa cell tumors, have to be considered in the differential diagnosis of TCC-O.
  • A recent analysis of a large series of advanced ovarian carcinomas treated by radical surgery and postoperative chemotherapy confirms studies that had suggested that TCC-O has a better prognosis (with current treatment) than that of the other histological types of ovarian carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1993 Apr;168(4):1178-85; discussion 1185-7 [8475964.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jul;15(3):257-65 [8811388.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1434-41 [14576476.001]
  • [Cites] Mod Pathol. 1998 Jul;11(7):656-64 [9688187.001]
  • [Cites] Int J Gynecol Pathol. 1987;6(1):29-39 [3570630.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):839-47 [2644014.001]
  • [Cites] Am J Clin Pathol. 1998 Feb;109(2):173-80 [9583889.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):195-9 [15790458.001]
  • [Cites] Histopathology. 2000 May;36(5):433-8 [10792484.001]
  • [Cites] Virchows Arch. 2001 Feb;438(2):181-91 [11253121.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):453-63 [15087664.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] Am J Clin Pathol. 1990 Apr;93(4):457-65 [2321577.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1267-72 [8958296.001]
  • (PMID = 17447068.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


66. Lu KH, Gershenson DM: Update on the management of ovarian germ cell tumors. J Reprod Med; 2005 Jun;50(6):417-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant germ cell tumors of the ovary are rare.
  • In contrast to epithelial ovarian cancer, malignant germ cell tumors occur primarily in girls and young women.
  • In a girl or young woman who presents with a pelvic mass, a gynecologist must consider the diagnosis of an ovarian germ cell tumor in the initial workup.
  • Elevated tumor markers may assist in determining the diagnosis preoperatively.
  • Appropriate intraoperative decision making is crucial to adequately treat and stage the cancer without compromising future fertility.
  • For patients with stage I dysgerminoma or stage I low grade immature teratoma, no additional chemotherapy is indicated.
  • However, patients with stage I disease of other germ cell histologies, as well as advanced-stage disease of all germ cell histologies, require adjuvant treatment with bleomycin, etoposide and cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fertility. Germinoma / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Female. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050566.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


67. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, Smyth J, Gabra H: Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer; 2004 May 15;100(10):2148-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the ovary: 19 years of prospective data from a single center.
  • BACKGROUND: A review of clinicopathologic features and outcome in women with carcinosarcoma of the ovary (also known as malignant mixed mesodermal tumor [MMMT]) compared with a group of women with serous adenocarcinoma (SAC) of the ovary was conducted.
  • METHODS: Between 1984 and 2002, 1568 patients with epithelial ovarian carcinoma and 70 patients with ovarian carcinosarcoma underwent treatment at the Edinburgh Cancer Centre.
  • Baseline variables were recorded prospectively and response to chemotherapy and progression-free and cause-specific survival between the groups were compared.
  • The objective response rate to platinum-based chemotherapy was found to be significantly lower in patients with carcinosarcoma (25% vs. 60%; P = 0.02).
  • Achieving optimal debulking at the time of initial surgery was found to be a highly significant factor in patients with carcinosarcoma with regard to determining outcome (median survival of 14.8 months for patients with optimally debulked International Federation of Gynecology and Obstetrics Stage III disease vs. 3.1 months for patients with suboptimally/nondebulked Stage III disease; P < 0.001).
  • Patients with carcinosarcoma differ from those with SAC with regard to having an older mean age of onset, an inferior response to platinum-based chemotherapy, and worse progression-free and cause-specific survival.
  • The extent of benefit from chemotherapy is unclear.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / mortality. Cystadenoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139057.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


68. Mandic A, Vujkov T, Malbasa Z: Paclitaxel or docetaxel combined with platinum in advanced ovarian cancer? J BUON; 2003 Jan-Mar;8(1):19-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial carcinoma of the ovary is one of the most common gynecologic malignancies and ranks 5th as a cause of cancer death in women, with half of all cases occurring in women aged over 65.
  • Because ovarian cancer is often asymptomatic in its early stages, most patients have widespread disease at the time of diagnosis.
  • Surgery is required for correct diagnosis and accurate staging, representing also the main form of treatment for early-stage disease which is confined to the ovaries.
  • In advanced stages (III and IV) where the tumor has spread beyond the pelvis, the initial surgical treatment is followed by chemotherapy.
  • Ovarian tumors are sensitive to chemotherapy, and most stage III and IV patients receive chemotherapy to increase survival, disease-free interval and improve quality of life (QoL).
  • Until the mid 1990s standard chemotherapy of advanced ovarian cancer involved a platinum compound, either cisplatin or carboplatin, administered either alone or in combination with cyclophosphamide.
  • New therapy standards emerged after the publication of a trial by the Gynecologic Oncology Group ( GOG) in 1996 and the first reports of an intergroup trial in 1998 that confirmed the GOG results.
  • These studies demonstrated that patients treated with cisplatin/paclitaxel had significantly higher response rates, progression-free survival and overall survival compared with the previous standard treatment of cisplatin plus cyclophosphamide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415862.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


69. Davidson B, Abeler VM: Primary ovarian angiosarcoma presenting as malignant cells in ascites: case report and review of the literature. Diagn Cytopathol; 2005 May;32(5):307-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian angiosarcoma presenting as malignant cells in ascites: case report and review of the literature.
  • Primary angiosarcoma of the ovary is a rare tumor, with less than 25 cases reported in the literature.
  • Tapping of peritoneal effusion showed groups of pleomorphic cells that were negative for epithelial and germ cell markers.
  • Immunohistochemistry performed on the surgical specimen of the ovary, and subsequently on the effusion specimen showed staining for endothelial markers.
  • The patient was treated post-operatively with chemotherapy, but died one year following diagnosis.
  • This is the first reported case of an ovarian angiosarcoma that metastasized to the peritoneal cavity, with a resulting malignant effusion.
  • Despite the rarity of metastasis from gynecological sarcomas in effusions, this possibility needs to be included in the differential diagnosis of malignant effusions that are negative for epithelial and germ cell markers.
  • [MeSH-minor] Adult. Ascitic Fluid / pathology. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Ovariectomy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15830366.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Amjad AI, Pal I: De novo primary squamous cell carcinoma of the ovary: a case of a rare malignancy with an aggressive clinical course. J Pak Med Assoc; 2008 May;58(5):272-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo primary squamous cell carcinoma of the ovary: a case of a rare malignancy with an aggressive clinical course.
  • Ovarian squamous cell carcinoma is a rare malignancy and the occurrence is attributable to malignant transformation of an existing ovarian dermoid cyst.
  • The de novo occurrence of squamous cell carcinoma of the ovary, in the absence of an antecedent ovarian dermoid, is extremely rare.
  • Abdominal CT was suggestive of a malignant neoplastic process.
  • Laparotomy confirmed a malignant tumour with involvement of the right adnexa and extension into the omentum and bowel.
  • Histopathology demonstrated squamous cell carcinoma arising from the right ovary with no co-existing ovarian dermoid.
  • The postoperative period was significant for disease progression despite adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Ovarian Neoplasms / diagnosis. Ovariectomy / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Colectomy / methods. Diagnosis, Differential. Disease Progression. Elective Surgical Procedures / methods. Female. Follow-Up Studies. Humans. Ileostomy / methods. Laparotomy. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655408.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


71. Sakuma M, Otsuki T, Yoshinaga K, Utsunomiya H, Nagase S, Takano T, Niikura H, Ito K, Otomo K, Tase T, Watanabe Y, Yaegashi N: Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases. Int J Gynecol Cancer; 2010 Jul;20(5):766-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases.
  • OBJECTIVES: Mature cystic teratoma (MCT) of the ovary rarely undergoes malignant transformation (MT).
  • Malignant transformation carries a significantly worse prognosis than epithelial ovarian cancer, regardless of whether postoperative chemotherapy or radiotherapy is applied.
  • The rarity of this tumor has posed a significant challenge to developing standardized postoperative management protocols.
  • The aim of this study was to review our experience with MT and to describe our current treatment practices.
  • Fifteen patients had squamous cell carcinoma (SCC), and 5 patients had other histological subtypes.
  • Eleven patients received adjuvant treatment: 8 were treated with chemotherapy, 2 with concurrent chemoradiation therapy, and 1 with radiation therapy.
  • Platinum-based chemotherapy was the first-line regimen.
  • Significant correlations between overall survival and age, stage, and residual tumor were presented (P = 0.044, P = 0.0107, P < 0.0001, respectively).
  • Four patients, however, were treated with adjuvant chemotherapy or concurrent chemoradiation therapy and survived more than 1 year.
  • Two cases of SCC treated with combination platinum/taxane chemotherapy temporarily responded.
  • In the other 2 cases of SCC, concurrent chemoradiation therapy with nedaplatin also resulted in tumor regression.
  • Adjuvant treatment has not been standardized, although our experience supports the use of combination platinum/taxane chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cell Transformation, Neoplastic. Female. Humans. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973266.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


72. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer; 2004 May 10;109(6):926-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
  • We evaluated whether tracer FDG uptake, quantified as an SUV by PET in ovarian epithelial tumors, correlates with clinical stage, tumor grade, cell proliferation and glucose metabolism, all of which are biomarkers for response to chemotherapy, prognosis and overall survival in ovarian cancer patients.
  • Seventeen patients suspected of having ovarian cancer by physical examination, tumor marker analysis and anatomic imaging (such as sonography, CT and/or MRI) underwent whole-body FDG-PET within the 2 weeks prior to surgery.
  • Seventeen epithelial ovarian tumor specimens (13 malignant tumors, 5 at stage I, 2 at stage II, 6 at stage III; 2 borderline tumors; and 2 benign lesions) were available for pathologic evaluation.
  • Therefore, glucose consumption, as determined by analysis of SUVs in FDG-PET, may be a noninvasive biomarker for ovarian epithelial tumors.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Ki-67 Antigen / metabolism. Monosaccharide Transport Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radionuclide imaging. Biomarkers, Tumor. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radionuclide imaging. Cell Division. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radionuclide imaging. Female. Glucose / metabolism. Glucose Transporter Type 1. Humans. Neoplasm Staging. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15027127.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Ki-67 Antigen; 0 / Monosaccharide Transport Proteins; 0 / Radiopharmaceuticals; 0 / SLC2A1 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


73. Suzuki M, Saga Y, Tsukagoshi S, Tamura N, Sato I: Recurrent ovarian clear cell carcinoma: complete remission after radiation in combination with hyperthermia; a case study and in vitro study. Cancer Biother Radiopharm; 2000 Dec;15(6):625-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent ovarian clear cell carcinoma: complete remission after radiation in combination with hyperthermia; a case study and in vitro study.
  • Since clear cell carcinoma of the ovary does not respond to conventional platinum-based chemotherapy, the prognosis of recurrent tumors is especially poor.
  • In a 51-year old female who underwent surgery for clear cell carcinoma of the ovary, a solitary metastatic carcinoma developed in the pelvic cavity seven months after the initial surgery.
  • The patient underwent a whole pelvic irradiation at a total dose of 65 Gy combined with hyperthermia.
  • Complete remission was achieved 46 months after treatment.
  • A study using gynecologic carcinoma cell lines showed that the mean 50% growth inhibitory dose of radiation was 1.2 +/- 0.4 Gy in several clear cell carcinoma cell lines.
  • The value did not significantly differ from those for serous carcinoma cell lines (2.3 +/- 1.2 Gy) and uterine cervical carcinoma cell lines (1.6 +/- 0.4 Gy).
  • Currently, no anticancer agents are effective for clear cell carcinoma.
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11190494.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. D'Angelo E, Prat J: Classification of ovarian carcinomas based on pathology and molecular genetics. Clin Transl Oncol; 2010 Dec;12(12):783-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant epithelial tumours (carcinomas) are the most common ovarian cancers and the most lethal gynaecological malignancies.
  • Based on light microscopy and molecular genetics, ovarian carcinomas are subdivided into at least five main subtypes that account for over 95% of cases and are inherently different diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, molecular events during oncogenesis, response to chemotherapy and outcome.
  • For successful subtype-specific treatment, reproducible pathological diagnosis of tumour cell type is critical.
  • Recent investigations have also demonstrated that a significant number of cancers traditionally thought to be primary ovarian tumours (particularly serous, endometrioid and clear cell carcinomas) originate in the fallopian tube and the endometrium and involve the ovary secondarily.
  • In this review we summarise recent advances in the molecular pathology, which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.
  • [MeSH-major] Ovarian Neoplasms / classification. Ovary / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Female. Humans. Neoplasms, Glandular and Epithelial / classification. Neoplasms, Glandular and Epithelial / genetics. Neoplasms, Glandular and Epithelial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2004 Feb;44(2):109-15 [14764054.001]
  • [Cites] Cancer Res. 1998 May 15;58(10 ):2095-7 [9605750.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):605-19 [16021566.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 [10749912.001]
  • [Cites] BMC Cancer. 2008 Jan 22;8:17 [18208621.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):342-6 [10053105.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1581-6 [9118042.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):139-52 [11812936.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1360-8 [15668893.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Obstet Gynecol. 2002 Jan;99(1):3-10 [11777502.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):469-73 [17765295.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):147-59 [15043303.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1344-7 [9537226.001]
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):281-7 [12151151.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):361-8 [16880307.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Hum Pathol. 2009 Sep;40(9):1213-23 [19552940.001]
  • [Cites] J Pathol. 2007 Feb;211(3):286-95 [17154249.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • (PMID = 21156408.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Ovarian epithelial cancer
  •  go-up   go-down


75. Matsuura Y, Kitajima M, Hachisuga T, Tanimoto A, Okura N, Kihara I: Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res; 2010 Aug;36(4):907-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings.
  • Malignant mixed müllerian tumor (MMMT) or carcinosarcoma of the female genital tract is a rare neoplasm.
  • Malignant ovarian tumor composed of müllerian epithelial tumor and malignant germ cell tumor is also rare, with most cases composed of endometrioid adenocarcinoma and yolk sac tumor.
  • Ovarian MMMT with malignant neuroectodermal components resembling immature teratoma is extremely rare.
  • We report a case of teratoid carcinosarcoma of the ovary occurring in a 40-year-old female.
  • The resected tumor measuring over 20 cm in diameter consisted of cystic and solid components and was very fragile.
  • Microscopic examination showed a heterogenous mixed tumor composed of malignant epithelial, malignant mesodermal and malignant neuroectodermal components.
  • There was no tumor immunoreactivity to alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and inhibin.
  • In spite of aggressive combination chemotherapy and three times of laparotomy, the patient died of disease 3 years 10 months after the initial treatment.
  • This quite rare ovarian tumor closely resembled nasopharyngeal tumors described as 'teratoid carcinosarcoma' is biologically aggressive.
  • Further cases need to be accumulated to make diagnosis and to determine a successful treatment modality.
  • [MeSH-major] Carcinosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Ovary / pathology. Ovary / surgery

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666968.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


76. Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Tropé C, Saatcioglu F: Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol; 2004 Jul;94(1):80-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Carcinoma of the ovary is the most fatal malignancy of the female genital tract in western countries.
  • The effectiveness of chemotherapy is limited by the acquisition of drug resistance.
  • The goal of this study was to investigate if KLK4 protein (hK4) is expressed in ovarian carcinoma lesions and if it is associated with paclitaxel resistance.
  • The overall response rate to weekly paclitaxel was 52% (24 of 46) and for patients with tumors resistant to standard three weekly paclitaxel treatment 48% (16 of 33).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Kallikreins / biosynthesis. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Cohort Studies. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Middle Aged. Molecular Sequence Data. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15262123.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


77. Bliumenberg AG, Gonikberg EM, Dederer LIu, Gorbacheva LB: [Comparative study of cytosolic proteins in normal and neoplastic ovaries by polyacrylamide electrophoresis]. Vopr Onkol; 2001;47(4):443-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The report discusses the data on cytoplasmic protein occurrence in ovarian tissue (106) obtained by polyacrylamide gel electrophoresis.
  • They were identified in normal ovarian tissue (15), benign tumor (16), primary malignant tumor (55) and tumor tissue after chemotherapy (20).
  • A band was detected in the area of molecular 36 cD in malignant epithelial tumor tissue which was not seen in either normal, benign tumor tissue or after successful chemotherapy.
  • [MeSH-major] Cytosol / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism. Proteins / metabolism
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11710287.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Proteins
  •  go-up   go-down


78. Navarini R, Pineda RL: Malignant mixed müllerian tumors of the ovary. Curr Opin Obstet Gynecol; 2006 Feb;18(1):20-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumors of the ovary.
  • PURPOSE OF REVIEW: Müllerian mixed malignant tumors of the ovary constitute an infrequently encountered group of malignant ovarian neoplasms, which are highly aggressive and respond poorly to treatment.
  • The clinical presentation of these tumors is similar to that of epithelial ovarian tumors, although they tend to manifest themselves at later stages of disease.
  • There are no useful biochemical markers: imaging diagnostic methods (ultrasound, computed tomography, magnetic resonance imaging) do not provide specific data.
  • The staging and primary treatment are always surgical.
  • Chemotherapy (platinum) can prolong survival, but there are no effective second-line treatments.
  • In order to improve therapeutic results, it will be necessary to design multicenter, cooperative studies including larger numbers of patients.
  • SUMMARY: In clinical practice, treatment options for these tumors are few; a rapid downhill course is the rule rather than the exception.
  • [MeSH-major] Mixed Tumor, Mullerian / diagnosis. Mixed Tumor, Mullerian / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493255.001).
  • [ISSN] 1473-656X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 15
  •  go-up   go-down


79. Wu M, Shen K, Lang J, Huang R, Huang H, Pan L: [Transitional cell carcinoma of the ovary: one kind of uncommon type of ovarian epithelial carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2002 Dec;37(12):733-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transitional cell carcinoma of the ovary: one kind of uncommon type of ovarian epithelial carcinoma].
  • OBJECTIVE: To evaluated clinico-biologic behavior, prognosis and relative prognostic factors of transitional cell carcinoma of the ovary.
  • METHODS: The clinical records of 58 patients with transitional cell carcinoma of the ovary, who received treatment in the department of Obstetrics and Gynecology, Peking Union Medical College Hospital in 20 years, were reviewed retrospectively.
  • 31% of them had bilateral ovary involvement, and the median level of CA(125) was (687 +/- 365) U/L.
  • Different courses of chemotherapy were given to all patients.
  • The Cox hazards regression model was used to analyze the possible prognostic factors and revealed that tumor residuals (P < 0.01), preoperative level of CA(125) (P < 0.01), bilateral ovary involvement (P < 0.05) and lymph node metastasis (P < 0.05) were the most important prognostic factors.
  • CONCLUSIONS: Transitional cell carcinoma of ovary is an uncommon type of ovarian cancer.
  • It usually behaves better prognosis when compared with papillary serous cystadenocarcinoma of the ovary.
  • [MeSH-major] Carcinoma, Transitional Cell / mortality. Ovarian Neoplasms / mortality

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12622917.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Soriţău O, Tomuleasa CI, Páll E, Virág P, Fischer-Fodor E, Foris V, Barbos O, Tatomir C, Kacsó G, Irimie A: Enhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer. Rom J Morphol Embryol; 2010;51(2):259-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer.
  • The main reason why epithelial ovarian cancer is difficult to treat is the unusual mechanism of dissemination that involves local invasion of pelvic and abdominal organs.
  • Because it has been proven that aggregates of malignant cells within the ascites of patients diagnosed with ovarian cancer represent an impediment to cure such cancers, in the present study we adopted suspension culture combined with anti-cancer regimens as a laboratory strategy for research of the initial process of peritoneal micrometastasis.
  • The acquired increased aggressiveness properties was confirmed by multidrug resistance assays and by their ability to grow in an anchorage-independent manner in vitro as tumor spheroids.
  • RESULTS: Cells selected after chemotherapy had a increased proliferative potential, eliminated Rhodamine 123 in culture and also formed spheroids in suspension.
  • CONCLUSIONS: Here we present direct evidence that the metastasis of human ovarian cancer may be a result of transformation and dysfunction of immature precursor cells in the ovary.
  • Also, spheroid formation may represent a key component of chemotherapy recurrence and a better understanding of these 3D structures can contribute to the development of new treatments for metastatic carcinoma.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Cell Line, Tumor. Drug Resistance, Neoplasm. Epithelium. Female. Humans. Neoplasm Metastasis. Spheroids, Cellular. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495740.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


81. Li M, Pan LY, Huang HF, Lang JH: [Epithelial ovarian tumors in adolescence: a study of clinical features and treatment]. Zhonghua Fu Chan Ke Za Zhi; 2004 Sep;39(9):598-601
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelial ovarian tumors in adolescence: a study of clinical features and treatment].
  • OBJECTIVE: To study the clinical feature, diagnosis and treatment of epithelial ovarian tumors in adolescent patients.
  • METHODS: A retrospective analysis was performed on 29 patients of epithelial ovarian tumors between the age of 13 and 19 during the period of 1983 - 2002 in Peking Union Medical College Hospital.
  • Twenty of the cases were with benign tumors, four with borderline, and five with malignant tumors.
  • The histological types included mucinous tumor in twenty-two cases, serous tumor in six, and endometroid tumor in one case.
  • Among the nine cases with borderline or malignant tumors, eight were at stage I and one at stage IIIc.
  • Of benign tumor group, an abdominal unilateral salpingo-oophorectomy was performed on nine cases.
  • The nine cases with borderline or malignant tumors underwent cytoreductive surgery and comprehensive staging surgery; fertility was preserved for eight of them.
  • A cisplatin combined chemotherapy was given to four patients with malignant tumors.
  • CONCLUSIONS: The incidence of epithelial ovarian tumors during adolescence increases with age.
  • Mucinous tumor is the most common histological type in adolescent patients.
  • The therapeutic strategy should be individualized, and surgical approach should consider both cure and preservation of fertility in malignant cases.
  • [MeSH-major] Carcinoma / therapy. Ovarian Neoplasms / therapy. Puberty
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Laparoscopy. Neoplasm Staging. Ovary / surgery. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15498186.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


82. Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P, Bukowski RM: Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Invest New Drugs; 2008 Dec;26(6):553-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temozolomide is an alkylating agent which crosses the blood brain barrier and has demonstrated antitumor activity against a broad range of tumor types, including malignant glioma, melanoma, non small cell lung cancer and carcinoma of the ovary and colon.
  • A Phase I trial was conducted to determine the toxicity of this combination in refractory solid tumor patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Survival Rate. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1998 Oct;25(5 Suppl 12):32-4 [9865710.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1377-82 [17416857.001]
  • [Cites] Cancer Treat Rev. 1997 Jan;23 (1):35-61 [9189180.001]
  • [Cites] Invest New Drugs. 1994;12(3):169-82 [7896535.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):98-103 [12468349.001]
  • [Cites] Clin Lung Cancer. 2002 May;3(4):254-8 [14662033.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4845-52 [1680023.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1455-61 [18300256.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8389-95 [16293869.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):90-6 [15598944.001]
  • [Cites] Cancer Res. 1998 Oct 1 ;58(19):4363-7 [9766665.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):309-17 [10037179.001]
  • [Cites] N Engl J Med. 1995 Apr 13;332(15):1004-14 [7885406.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):203-7 [12675312.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):420-5 [11786569.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1022-30 [10576660.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):1996-2004 [15558071.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Anticancer Drugs. 1997 Jan;8(1):92-7 [9147618.001]
  • [Cites] Clin Cancer Res. 1997 Jul;3(7):1093-100 [9815788.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):61-5 [15719277.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):742-7 [10762746.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1212-9 [10715290.001]
  • (PMID = 18626572.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


83. Geetha P, Nair MK: Granulosa cell tumours of the ovary. Aust N Z J Obstet Gynaecol; 2010 Jun;50(3):216-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumours of the ovary.
  • Granulosa cell tumours are rare, potentially malignant sex cord stromal tumours of the ovary.
  • Many of them are hormone-producing and this property helps them to present early unlike other epithelial ovarian cancers.
  • As a result, most of them will be in an early stage at the time of initial diagnosis.
  • The tumour can manifest in young girls as a juvenile form and conservative management with unilateral salpingo-opherectomy may be an option in them as 95% are unilateral.
  • Surgery is the treatment of choice and initial staging laparatomy a determinant recurrence.
  • Advance stage of the tumour, its size (>5 cm), mitotic figures (>10/hpf), nuclear atypia and absence of call-exner bodies are poor prognostic factors.
  • Tumour markers such as inhibin and estradiol are useful in follow-up.
  • Chemotherapy, radiotherapy and hormone replacement therapy have very little role in the initial treatment and may be suggested in case of recurrences.
  • With appropriate treatment, a better survival rate can be achieved as against other ovarian malignancies.
  • [MeSH-major] Granulosa Cell Tumor / diagnosis. Granulosa Cell Tumor / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618236.001).
  • [ISSN] 1479-828X
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


84. Lindboe CF: Large cell neuroendocrine carcinoma of the ovary. APMIS; 2007 Feb;115(2):169-76
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the ovary.
  • Large cell neuroendocrine carcinoma of the ovary is a recently described tumour entity that is now included in the WHO classification of primary ovarian neoplasms.
  • Although mostly in stage I at diagnosis, this tumour shows an aggressive clinical behaviour with subsequent metastases and mean survival is less than one year.
  • In addition to the neuroendocrine carcinoma, most cases also have a malignant surface epithelial tumour component.
  • I here report a 64-year-old woman who was operated on for a right-sided ovarian large cell neuroendocrine carcinoma without a surface epithelial component, which constitutes only the second reported tumour of this "pure" kind.
  • The patient was treated postoperatively with chemotherapy.
  • She developed bleomycin-induced lung fibrosis that responded well to treatment with steroids.
  • There have been no signs of local tumour recurrence or metastases at follow-up examinations during the first 9 months after the operation.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295684.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


85. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD: Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther; 2006 Jan;5(1):22-7
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor biopsies were taken before and after starting the drug to assess for microvessel density by CD 31 and cell proliferation by Ki67 immunohistochemistry.
  • There was one episode of grade 4 angioedema in the 1600 mg bid dose level 38 days into 2ME2 treatment.
  • A patient with clear cell carcinoma of the ovary had a partial response at 1600 mg bid dose level lasting over three years.
  • 2ME2 treatment had no effect on microvessel density (CD31 immunostaining) and cell proliferation (Ki-67 immunostaining).
  • A new formulation of 2ME2 with improved bioavailability is currently being developed.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Estradiol / analogs & derivatives. Maximum Tolerated Dose. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Apoptosis. Capillaries / drug effects. Cell Proliferation / drug effects. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357512.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol
  •  go-up   go-down


86. Skírnisdóttir I, Seidal T, Karlsson MG, Sorbe B: Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol; 2005 Jan;26(1):177-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
  • Clear cell carcinoma of the ovary is considered to be a specific subtype among the epithelial ovarian malignancies.
  • From a complete series of 226 patients with epithelial ovarian carcinomas in FIGO stages I-II, 28 patients with clear cell carcinomas were selected and the clinical and biological characteristics of these tumors were compared with the remaining non-clear cell carcinomas.
  • All patients underwent primary staging laparotomy followed by adjuvant radiotherapy or chemotherapy.
  • No difference was found in the rate of tumor recurrences or survival for patients with clear cell and non-clear cell carcinomas.
  • Clear cell carcinomas of the ovary should be regarded as a separate entity among the epithelial ovarian carcinomas and they differ with regard to both clinical and biological characteristics when compared with non-clear cell tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Neoplasm Staging. Ploidies. Prognosis. Recurrence


87. Chen P, Hu WM, Wang PH, Suen JH: Recurrent breast cancer presents as a single solid ovarian mass and ascites. Taiwan J Obstet Gynecol; 2006 Dec;45(4):356-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, aside from the primary origin, a metastatic lesion should be considered, since the ovary is frequently metastasized from cancers of other organs, such as the genital tract, gastrointestinal tract, and breast.
  • CASE REPORT: A 47-year-old woman with a history of right breast infiltrating lobular carcinoma, T3N0M0, grade 3, was treated with modified radical mastectomy and axillary lymph-node dissection in July 2001.
  • Tumor recurrence was noted in December 2003.
  • Therefore, she underwent palliative radiotherapy and various kinds of chemotherapy.
  • However, metastatic carcinoma of the ovary of breast origin was finally diagnosed.
  • [MeSH-major] Ascites / etiology. Breast Neoplasms / pathology. Carcinoma / secondary. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175500.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Lin CH, Liu FS, Ho ES: Transitional cell carcinoma of the ovary. Taiwan J Obstet Gynecol; 2006 Sep;45(3):268-71
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ovary.
  • OBJECTIVE: Transitional cell carcinoma (TCC) of the ovary is a rare, recently recognized, subtype of ovarian surface epithelial cancer.
  • We present a case of TCC of the ovary, managed by staging operation and followed by postoperative chemotherapy with carboplatin and cyclophosphamide.
  • Pelvic sonography and abdominal computed tomography showed a pelvic mass measuring 210 x 165 x 203 mm.
  • After surgery, the pathologic report of the left ovarian tumor was TCC, grade 2-3, stage IA.
  • The patient then underwent four cycles of postoperative chemotherapy with carboplatin and cyclophosphamide.
  • CA-125 levels declined to within the normal range after the first cycle of chemotherapy.
  • CONCLUSION: TCC of the ovary is a rare subtype of epithelial ovarian cancer.
  • It differs from malignant Brenner tumor by the absence of a benign or borderline Brenner component.
  • Surgical resection is the primary therapeutic approach, and patient outcomes after chemotherapy are better than for other types of common epithelial ovarian cancers.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Hysterectomy. Ovarian Neoplasms / surgery. Ovariectomy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fallopian Tubes / surgery. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175479.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


89. Berman ML: Future directions in the surgical management of ovarian cancer. Gynecol Oncol; 2003 Aug;90(2 Pt 2):S33-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) the extent of surgery indicated in the primary surgical management of advanced-stage disease, (2) the prognostic features of ovarian cancer, (3) the role of interval debulking following neoadjuvant chemotherapy, (4) the role of fertility-sparing surgery, (5) the role of "second-look" surgery, and (6) the role of secondary tumor debulking.
  • RESULTS: The criteria for justifying extraordinary measures to reduce the tumor burden in patients with advanced disease to an "optimal" state have not been established.
  • Likewise, the factors that influence prognosis and treatment are not well defined or understood.
  • Interval debulking following neoadjuvant chemotherapy is a promising approach to the management of advanced-stage disease, but no clinical trials have been conducted comparing it to primary surgery followed by chemotherapy.
  • Fertility-sparing surgery may be appropriate even for women with frankly malignant epithelial cancers when disease is confined to one ovary.
  • Finally, few data show a benefit from secondary tumor resection in patients who progress while undergoing first-line chemotherapy or have a recurrence soon afterward.
  • [MeSH-minor] Female. Forecasting. Gynecologic Surgical Procedures / methods. Humans. Neoadjuvant Therapy. Second-Look Surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2004 Jul;94(1):235-6; author reply 238-40 [15262151.001]
  • [CommentIn] Gynecol Oncol. 2004 Jul;94(1):236-8; author reply 238-40 [15262152.001]
  • (PMID = 12928004.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


90. Kerbrat P, Lhommé C, Fervers B, Guastalla JP, Thomas L, Basuyau JP, Duvillard P, Cohen-Solal C, Dauplat J, Tournemaine N: [Standards, options, and recommendations for initial management of patients with malignant ovarian epithelial tumors]. Presse Med; 2000 Dec 09;29(38):2116-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standards, options, and recommendations for initial management of patients with malignant ovarian epithelial tumors].
  • [Transliterated title] Standards, options et recommandations pour la prise en charge initiale des patientes atteintes de tumeurs épithéliales malignes de l'ovaire.
  • Suprapubic and transvaginal pelvic ultrasound exploration is indicated for suspected ovarian tumor (standard).
  • Systematic preoperative computed tomography is not recommended (standard).
  • Surgery for cancer of the ovary is a specialized procedure requiring skill in cancer, gynecology, visceral surgery and laparoscopic surgery.
  • If the patient is referred to a specialized center after a primary procedure considered to be inadequate, a new procedure is recommended for staging.
  • Residual tumor volume after the primary procedure has prognostic value.
  • For patients with grade IA G1 tumors, there is no indication for complementary treatment (standard).
  • OPTIONS: no complementary treatment, complementary chemotherapy using platinum, complementary external abdominopelvic radiotherapy.
  • A complementary treatment is recommended for grades IC and IIA.
  • Complementary treatment for grades IIB (no residual tissue), IIC (with residual tissue), III (no residual tissue), is based on: complementary chemotherapy with platinium, complementary external abdominopelvic radiotherapy (options).
  • Complementary treatment for advanced forms (IIB (with residual tissue), IIC (with residual tissue), III (with residual tissue) and IV) is based on polychemotherapy with platinium (standard).
  • The chemotherapy work-up includes physical examination, assay of serum markers (particularly CA125) and abdominopelvic computed tomography (proof level B) (standard).
  • [MeSH-major] Carcinoma / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials as Topic. Female. Humans. Neoplasm Staging. Patient Care Planning

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11147056.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


91. Chang WC, Sheu BC, Lin MC, Chow SN, Huang SC: Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):549-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report.
  • Epithelial ovarian tumors of borderline malignancy are tumors with histologic features and biologic behavior between benign and frankly malignant epithelial ovarian neoplasms.
  • Here, we present a 35-year-old patient with carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian tumor of borderline malignancy.
  • Foci of intraepithelial carcinoma (about 10%) without stromal invasion are also noted.
  • Total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and omentectomy were performed, and the frozen pathology during operation showed mucinous tumor of borderline malignancy of left ovary on April 18, 2002.
  • The patient was followed at our outpatient department for 19 months after operation and was free of the disease without any adjuvant chemotherapy.
  • It is difficult to determine whether intestinal-type borderline mucinous tumors with intraepithelial carcinoma are associated with a worse prognosis compared with those with epithelial atypia alone due to disparate results in the published literature.
  • In contrast, most patients with mural nodules of anaplastic carcinoma have had a malignant, often rapid, course.
  • However, too few cases of carcinosarcoma-like mural nodule in mucinous tumor have been published to warrant a conclusion regarding their prognosis.

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882184.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Vig-Varga E, Benson EA, Limbil TL, Allison BM, Goebl MG, Harrington MA: Alpha-lipoic acid modulates ovarian surface epithelial cell growth. Gynecol Oncol; 2006 Oct;103(1):45-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-lipoic acid modulates ovarian surface epithelial cell growth.
  • Clinical and laboratory data suggest that inflammation can lead to tumor progression.
  • We hypothesized that restoring intracellular redox control would inhibit inflammation and subsequently tumor progression.
  • Our studies were designed to investigate the effect of alpha-lipoic acid (ALA), a naturally occurring antioxidant, on a key inflammatory signaling pathway and cell proliferation in normal and tumorigenic ovarian surface epithelial cells.
  • METHODS: Normal and tumorigenic ovarian surface epithelial cells were isolated as described by Roby and coworkers [Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawpik O, Persons DL, Smith PG, Terranova PF, Development of a syngeneic mouse model for events related to ovarian cancer.
  • RESULTS: Our results reveal that ALA selectively inhibits the growth of tumorigenic as compared to non-tumorigenic ovarian surface epithelial cells.
  • CONCLUSIONS: Our studies are the first to show that ALA treatment has a growth inhibitory effect on malignant surface epithelial cells of ovarian origin.
  • [MeSH-major] Epithelial Cells / drug effects. Ovarian Neoplasms / drug therapy. Thioctic Acid / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Growth Processes / drug effects. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Disease Models, Animal. Female. Mice. Mice, Inbred C57BL. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. Ovary / cytology. Ovary / drug effects. Ovary / metabolism. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16574204.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 73Y7P0K73Y / Thioctic Acid
  •  go-up   go-down


93. Makar AP: Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer; 2000 Jun;7(2):85-93
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone therapy in epithelial ovarian cancer.
  • Although epidemiologic studies, animal experiments and receptor studies have shown that not only normal ovaries but also many malignant ovarian tumors can be considered as endocrine related and hormone dependent, the place of hormonal therapy in the management of patients with ovarian cancer remains unsettled.
  • Most trials of hormonal treatment in ovarian cancer have been retrospective, involved only limited numbers of patients, and lacked important patient-related data and information pertaining to tumor characteristics.
  • A literature review shows that response to hormonal therapy even in a preterminal setting, is modest, with about 8% objective response but almost no side effects.
  • In a similar patient setting, more toxic therapeutic agents do not yield a better response.
  • The place of hormonal therapy in the management of patients with epithelial ovarian cancer needs more thorough evaluation in well-designed randomized trials.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Estrogen Antagonists / adverse effects. Estrogen Antagonists / therapeutic use. Female. Hormones / biosynthesis. Humans. Neoplasms, Hormone-Dependent / drug therapy. Ovary / metabolism. Postmenopause. Tamoxifen / adverse effects. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10903526.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Hormones; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 100
  •  go-up   go-down


94. Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T, Sato N: Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res; 2004 Aug 1;64(15):5442-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis for patients with osteosarcoma who do not respond to current chemotherapy protocols still remains poor.
  • Toward the goal of establishing efficacious peptide-based immunotherapy for those patients, we previously developed an autologous pair of CTLs and an osteosarcoma cell line.
  • Reverse transcription-PCR analysis revealed that PBF was expressed in 16 of 19 cases of bone and soft-tissue sarcoma cell lines (5 of 6 of osteosarcoma lines) and 57 of 76 sarcoma tissue samples (11 of 14 of osteosarcoma tissues).
  • Also, PBF was expressed in 10 of 13 epithelial cancer cell lines and 20 of 34 of cancer tissues.
  • In contrast, PBF was detected in some normal organs including ovary, pancreas, spleen, and liver by reverse transcription-PCR but was restricted in the cytoplasm by immunostaining and undetectable by Western blotting.
  • These findings suggest that PBF is a shared tumor-associated antigen, which may serve as a source of peptides applicable to peptide-based immunotherapy for osteosarcoma and other malignant tumors.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15289353.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A Antigens; 0 / Peptide Fragments
  •  go-up   go-down


95. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • The latter case had a dermoid cyst in the contralateral ovary.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


96. Syed V, Ho SM: Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene; 2003 Oct 9;22(44):6883-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL.
  • Progesterone (P4) has been implicated as a protective factor for epithelial ovarian cancers, yet little is known about its mechanism of action.
  • We previously reported that pregnancy-equivalent doses of P4 inhibited the growth of normal and malignant human ovarian surface epithelial (HOSE) cells.
  • Here, we investigated how P4-induced cell death in two immortalized normal (HOSE 642, HOSE 12-12) and two malignant (OVCA 429, OVCA 432) HOSE cell lines.
  • The exposure of HOSE or OVCA cell cultures to 10(-6) M P4 induced time-dependent increases in early and late apoptotic cells and activation of caspase-8 and -3, but not that of caspase-9.
  • The exposure of HOSE or OVCA cells to an activating anti-Fas antibody induced cell loss, whereas treatment of cells with a blocking anti-FasL antibody reduced the P4-induced cell loss.
  • These results reveal for the first time that P4 induces apoptosis in HOSE and OVCA cells via activation of a caspase-8-initiated Fas/FasL signaling pathway.
  • [MeSH-major] Apoptosis / drug effects. Gene Expression Regulation, Neoplastic. Membrane Glycoproteins / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism. Progesterone / pharmacology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Amino Acid Chloromethyl Ketones / pharmacology. Caspase 8. Caspase 9. Caspases / drug effects. Caspases / metabolism. Cell Division / drug effects. Dose-Response Relationship, Drug. Drug Therapy, Combination. Enzyme Activation. Enzyme Inhibitors / pharmacology. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Fas Ligand Protein. Female. Humans. Middle Aged. Signal Transduction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534535.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA091250; United States / NCI NIH HHS / CA / CA94221; United States / NIDDK NIH HHS / DK / P30 DK32520
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Enzyme Inhibitors; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 4G7DS2Q64Y / Progesterone; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases
  •  go-up   go-down


97. Dalloul M, Sherer DM, Gorelick C, Serur E, Zinn H, Sanmugarajah J, Zigalo A, Abulafia O: Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma. Ultrasound Obstet Gynecol; 2007 Feb;29(2):236-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bilateral ovarian enlargement may reflect benign or malignant processes of the ovary.
  • Ovarian malignancies include epithelial, stromal and germ-cell tumors.
  • Primary malignancies that may exhibit metastases to the ovaries include gastrointestinal, breast and soft tissue tumors such as lymphoma.
  • Subsequent computerized tomography (CT) imaging depicted a large retroperitoneal tumor, CT-guided biopsy of which revealed diffuse large B cell lymphoma.
  • The patient responded well to chemotherapy with significant shrinkage of the tumor, and reappearance of normal findings on ovarian sonography.
  • This case demonstrates that bilaterally enlarged ovaries may be the first clinical evidence of a large retroperitoneal tumor and that in such cases CT imaging may be warranted.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Ovarian Neoplasms / pathology. Ovary / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Hypertrophy / etiology. Hypertrophy / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 17252529.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


98. Noack F, Schmitt M, Bauer J, Helmecke D, Krüger W, Thorban S, Sandherr M, Kuhn W, Graeff H, Harbeck N: A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications. Int J Biol Markers; 2000 Jan-Mar;15(1):100-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications.
  • At the time of primary therapy (surgery, systemic chemotherapy and/or radiation), disseminated tumor cells in the bone marrow can be found in almost one-third of patients with cancer of the breast, ovary, esophagus, stomach, colon, and other solid tumors.
  • Whereas the prognostic impact of the mere presence of these cells is still a matter of debate, it has been shown that expression of tumor-associated antigens in disseminated tumor cells is linked to more aggressive disease.
  • Therefore, further characterization of disseminated tumor cells at the protein and gene level has become increasingly important.
  • To date, the most common detection method for disseminated tumor cells in the bone marrow is an immunocytochemical approach using cytokeratin-directed antibodies for detection of epithelial cells and the APAAP system for their visualization.
  • We have established a new double immunofluorescence technique enabling simultaneous detection, phenotyping, and antigen quantification of disseminated tumor cells.
  • This protocol, originally designed for disseminated tumor cells in bone marrow, can also be applied to disseminated tumor cells in blood, to leukapheresis cells or to cells present in malignant ascites or other malignant effusions.
  • The tumor cells detected may be used for gene and mRNA analyses.
  • Furthermore, disseminated tumor cells also represent interesting targets for clinical studies on patient prognosis or prediction of therapy response as well as for specific tumor-biological therapies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow / pathology. Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10763150.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.4.21.- / Plasminogen Activators
  • [Number-of-references] 22
  •  go-up   go-down


99. He X, Lin B, Kong L, Zhang J: The potential mechanism of chemosensitive difference between 2 types of ovarian cancer. Saudi Med J; 2007 Jul;28(7):1044-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential mechanism of chemosensitive difference between 2 types of ovarian cancer.
  • OBJECTIVE: To study the potential molecular mechanism of chemosensitive difference between human malignant epithelial and germ cell tumor of the ovary by testing the expression of p53 (mutation), Bcl-2, topoisomerase II alpha (Topo II alpha).
  • METHODS: Immunohistochemical analysis was performed on paraffin embedded tumor tissue microarray from malignant epithelial (n=53) and germ cell tumor of the ovary (n=25) in the Department of Gynecology and Obstetrics, Second West China Hospital of Sichuan University, China from the year 2000 to 2004.
  • The expression of p53, Bcl-2 and Topo II alpha in the 2 types of ovarian cancer was compared and data were analyzed by student t test, Wilcoxon rank sum test and Spearman rank correlation test.
  • RESULTS: The expression of p53 (mutation) in ovarian epithelial cancers (56.6%) was significantly higher than that in the malignant germ cell tumors of the ovary (28%), whereas the expression of Bcl-2 and Topo II alpha had no significant difference between the 2 groups.
  • The expression of p53, Bcl-2 and Topo II alpha had no relationship with the Federation Internationale de Gynecologie Obstetrique (FIGO) stage.
  • The age, FIGO stage and the chemotherapy response were significantly different between the 2 groups.
  • Our results suggest that p53 may have a role on the difference of chemosensitivity between human malignant epithelial and germ cell tumor of the ovary.
  • [MeSH-major] Antigens, Neoplasm / analysis. Carcinoma / genetics. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Neoplasms, Germ Cell and Embryonal / genetics. Ovarian Neoplasms / genetics. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603707.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


100. Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, Hirte HW: Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol; 2006 Feb;17(2):334-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On day 1, following antiemetic prophylaxis with dexamethasone and a serotonin type 3(A) receptor (5HT3) inhibitor, UCN-01 was infused over 3 h, followed by T infused over 30 min.
  • Primary tumor types: ovary/peritoneal (23 patients), colon (three patients), salivary gland (two patients), others (five patients).
  • All patients were eligible for adverse event (AE) analysis and 22 patients were eligible for survival and tumor response analysis.
  • Most common drug-related AEs were mild (grade 1-2).
  • Best response for 22 evaluable patients was PD (8), SD for at least six cycles (12), PR (1: carcinoma of ovary, dose level 2) and one not assessable.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284058.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-1701
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7BU5H4V94A / 7-hydroxystaurosporine; 7M7YKX2N15 / Topotecan; H88EPA0A3N / Staurosporine
  •  go-up   go-down






Advertisement